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ABSTRACT 
Glial cell line-derived neurotrophic factor (GDNF) enhances survival of dopamine (DA) 
neurons in vitro, protects DAergic neurons in animal models of Parkinson’s disease (PD), 
stimulates DA neuron function, regulates postnatal development and supports DA neurons 
during adulthood. GDNF utilizes a multireceptor complex consisting of a ligand-binding 
co-receptor GDNF family receptor alpha 1 (GFRα1) and a signal-transducing receptor. 
The major signaling receptor of GDNF is the receptor tyrosine kinase Ret, although 
alternative signaling receptors have been found. GDNF and its receptors are considered 
important targets for developing new therapies that would ameliorate the degeneration of 
DA neurons and loss of DA that underlie movement impairments in PD.  
The present study investigated the role and significance of Ret signaling in the 
nigrostriatal DAergic system using mutant mice with a point mutation in Ret, which leads 
to constitutive activation of the Ret receptor tyrosine kinase and causes the cancer 
syndrome called multiple endocrine neoplasia type B (MEN2B). Immunohistochemical, 
neurochemical and molecular alterations in the DAergic system, as well as the behavior of 
the MEN2B mice, were studied. Particularly, we explored striatal DAergic 
neurotransmission in the MEN2B mice by using classical pharmacological tools as well as 
in vivo voltammetry. Also, in order to clarify the role of Ret in neuroprotection we studied 
effects of toxins on the DAergic system of MEN2B mice.  
We found markedly increased tissue DA concentrations, increased number of DA cells 
in the substantia nigra, elevated TH and DAT levels in the striatum and increased 
sensitivity to the stimulatory effects of cocaine in the MEN2B mice with constitutively 
active Ret. Also, synthesis, storage, release and uptake of DA in the striatum were found 
to be enhanced in the MEN2B mice. Finally, constitutive Ret activity protected DA cell 
bodies against neurotoxicity but was ineffective in protecting their axonal terminals in the 
striatum.  
In conclusion, this study showed that the constitutive Ret signaling supports and 
protects brain DA neurons, and promotes the DAergic phenotype, implicating Ret as an 
important signaling receptor for GDNF in the brain DAergic system. 
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1. INTRODUCTION 
 
Parkinson’s disease (PD) is an age-related, progressive neurodegenerative disorder that 
manifests with impairments of motor function. The motor symptoms of PD result from 
progressive degeneration of dopamine (DA) neurons in the substantia nigra pars compacta 
(SNpc) and a consequent reduction in striatal dopamine levels (Olanow, 2004). The 
therapy of PD is symptomatic, based on dopamine replacement, and currently no therapy 
that can stop or reverse progressive degeneration of DA neurons exists. 
Neurotrophic factors are generally described as naturally occurring polypeptides that 
support the development and survival of neurons. The first neurotrophic factor, nerve 
growth factor (NGF) was discovered more than 50 years ago (Levi-Montalcini, 1987) and 
since then, as the field of neurotrophic factors has advanced, many new neurotrophic 
factors have been discovered (Hefti, 1997; Skaper and Walsh, 1998). One of them is the 
glial cell line-derived neurotrophic factor (GDNF), which has been shown to enhance the 
survival and differentiation of midbrain DA neurons in vitro (Lin et al., 1993) and to have 
prominent beneficial effects on the compromised DAergic system in the animal models of 
PD (Hoffer et al., 1994; Kirik et al., 2004). Thus, by the virtue of its neuroprotective 
properties for nigrostriatal DA neurons, GDNF attracted interest as a potential therapeutic 
agent for PD, eventually reaching clinical trials in PD patients (Gill et al., 2003; Nutt et 
al., 2003; Slevin et al., 2005; Lang et al., 2006). In addition, the identification of three 
GDNF-related proteins, neurturin, artemin and persephin, expanded the GDNF family of 
neurotrophic factors (Baloh et al., 2000).  
In parallel, extensive research on the mechanisms of action and physiological role of 
GDNF was proceeding. It was found that GDNF exerts its physiological actions via a 
multicomponent receptor complex, which consist of the ligand-binding coreceptor GFRα1 
and signal transducing receptor tyrosine kinase Ret (Airaksinen et al., 1999). However, 
more recently Ret-independent GDNF signaling has also been described (Paratcha et al., 
2003). In addition to survival-promoting effects on DA neurons, GDNF appears to exert 
neurotrophic effects on various neuronal populations, and also to have various functions 
outside of the nervous system (Airaksinen and Saarma, 2002). However, as mutant mice 
lacking either GDNF or its receptors die at birth, and specific deletion of Ret from DA 
neurons revealed significant alteration only in the aging brain DAergic system, the 
physiological roles of GDNF and its signaling receptor Ret in the developing and adult 
brain DA neurons have remained largely unclear (Airaksinen and Saarma, 2002; Jain et 
al., 2006; Kramer et al., 2007). Thus, besides analyzing loss-of-function mutants, use of 
animal models with increased GDNF/Ret signaling might prove to be a useful and 
complementary approach. 
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2. REVIEW OF THE LITERATURE 
2.1 Brain DA systems 
In the mid 1950s, Carlsson and co-workers showed that DA functions as a transmitter in 
the CNS independently of its role as a precursor in the synthesis of noradrenaline and 
adrenaline (Carlsson et al., 1957; Carlsson, 1959). Since then, interest in DA has 
dramatically increased as a result of its involvement in a broad array of behaviors and 
disorders, such as control of motor behavior, attention, reward and in the pathologies of 
Parkinson’s disease, addiction to drugs of abuse and schizophrenia. 
DA neurons in the mammalian brain are localized in nine distinctive cell groups, from 
A8 to A16 (Dahlström and Fuxe, 1984; Hökfelt et al., 1984; Björklund and Dunnett, 
2007). The primary dopaminergic nuclei in the brain are the substantia nigra pars 
compacta (A9), ventral tegmental area (VTA, A10), retrorubral area (A8), all of which 
reside in the ventral midbrain, and the arcuate nucleus (A12) of the hypothalamus (Figure 
2.1A). In mice, there are about 20 000 - 30 000 DAergic cells in the A8, A9 and A10 cell 
groups, with about half of the cells located in the SNpc (Björklund and Dunnett, 2007). 
Cells of the SNpc project to the basal ganglia nuclei caudate and putamen, forming the 
nigrostriatal DAergic pathway. In addition, a minor part of the nigrostriatal DA pathway 
consists of axons from the retrorubral field (A8) projecting to the striatum. Axons of the 
nigrostriatal pathway run alongside fibers containing noradrenaline (NA) and serotonin (5-
HT) via the medial forebrain bundle (MFB). The nigrostriatal system is involved in the 
control of motor behavior, learning of motor programs and habit formation. The A10 cells 
innervate limbic structures, such as the nucleus accumbens, amygdala, hippocampus, 
septum and olfactory tubercle, forming mesolimbic DA pathway. Also, the A10 cells 
project to cortical areas including medial prefrontal, cingulate and entorhinal cortices and 
constitute the mesocortical DA pathway. The mesolimbic pathway is involved in the 
control of emotions and reward as well as control of motor behavior. The mesocortical 
pathway regulates higher cognitive functions, learning and reward. It should be noted that 
this widely used early classification is rather an oversimplification, and with help of more 
advanced methods, it has been more recently shown that DA neurons projecting to the 
striatal, limbic and cortical areas are partially intermixed (Björklund and Dunnett, 2007).  
The nigrostriatal, mesolimbic and mesocortical pathways are the so-called long, 
ascending DA pathways that link ventral midbrain with forebrain structures. In the 
hypothalamus, arcuate (A12) and periventricular (A14) DAergic nuclei project to the 
intermediate lobe of the pituitary and into the median eminence, forming the 
tuberoinfundibular pathway of intermediate length that regulates the pituitary gland 
function and prolactin release. Additionally, there are some DAergic interneurons in the 
olfactory cortex, medulla and retina (Rang et al., 1999; Cooper et al., 2003). This thesis is 
focused on the nigrostriatal DAergic pathway. 
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Figure 2.1. (A) Schematic representation of the ascending DAergic pathways originating in the 
substantia nigra pars compacta (A9), ventral tegmental area (A10) and retrorubral field (A8). (B) 
Schematic diagram of basal ganglia-thalamocortical circuitry. Inhibitory connections are depicted 
as black arrows, and excitatory connections as white arrows. Putamen is a major input nucleus 
and GPi (globus pallidus internal segment) and SNpr (substantia nigra pars reticulata) are the 
major output nuclei of the basal ganglia; D1 and D2, dopamine receptors; GPe (globus pallidus 
external segment); STN (subthalamic nucleus); thalamus (Thal); SNpc (substantia nigra pars 
compacta). Neurons containing DA (dopamine), GABA (γ-aminobutyric acid) and GLU 
(glutamate) are shown as indicated. Modified from (Wichmann and DeLong, 1996; Björklund and 
Dunnett, 2007). 
2.1.1 DA synthesis, storage and metabolism 
At the axonal terminal, DA is synthesized from the amino acid tyrosine, which is actively 
transported across the blood-brain barrier (Figure 2.2). The first and rate-limiting step in 
the biosynthesis of DA (and other catecholamines) is catalyzed by the enzyme tyrosine 
hydroxylase (TH) and results in the formation of 3,4-dihydroxyphenylalanine (DOPA) 
(Carlsson and Lindqvist, 1973, 1978). During the next step, DOPA is rapidly converted to 
DA by aromatic amino acid decarboxylase (AAADC; Figure 2.2).  
Since tyrosine hydroxylase is the rate-limiting enzyme in biosynthesis of DA, 
regulation of its activity represents a central means of controlling the neuronal 
concentrations of DA. The activity of TH can be modulated by two mechanisms: medium- 
to long-term regulation of gene expression and short-term direct regulation of enzyme 
activity (feedback inhibition and phosphorylation) (Kumer and Vrana, 1996; Fujisawa and 
Okuno, 2005). End-product feedback inhibition of TH by intraneuronal DA, which 
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competes with cofactor tetrahydrobiopterin (BH4) for a binding site on TH, acts as a 
sensor of the local concentrations of DA and is predominant during low neuronal activity. 
Phosphorylation of TH by different protein kinases rapidly activates TH and increases DA 
synthesis during period of increased impulse flow. Phosphorylation causes a 
conformational change in the TH protein that leads to its increased affinity for cofactors 
and reduced affinity for dopamine (Kumer and Vrana, 1996; Dunkley et al., 2004). In 
contrast, activation of D2 autoreceptors by extraneuronal DA leads to inhibition of TH and 
decreased synthesis of DA (Missale et al., 1998). 
Newly synthesized DA is sequestered from the cytoplasm into storage vesicles by 
vesicular monoamine transporter 2 (VMAT2; Figure 2.2). Within the nerve terminal, 
vesicles reside in distinct “pools” that include a releasable pool that maintains exocytosis 
during mild stimulation and storage pool that is depleted only after the stimulation 
surpasses normal limits (Rizzoli and Betz, 2005). The releasable pool of DA contains 
newly synthesized DA and is sensitive to blockade of TH, whereas the storage pool of 
dopamine serves as a depot that contains most of the intracellular dopamine and is 
sensitive to the blockade of VMAT2 (Yavich, 1996). The DA stores are not static, but 
exist in highly dynamic state where active and rapid packing of DA into vesicles 
counterbalances passive outward leakage of DA from vesicles. Cytosolic DA, resulting 
from leakage of DA from the vesicles, reuptake of released DA, and newly synthesized 
transmitter, if not packed in vesicles, are metabolized by monoamine oxidase (MAO) to 
yield 3,4-dihydroxyphenylacetic acid (DOPAC; Figure 2.2) (reviewed by Eisenhofer et al., 
2004). Thus, short-term accumulation of DOPAC in mouse brain is taken as a reflection of 
the activity of DA neurons (Cooper et al., 2003). There are two forms of MAO, namely 
MAO-A and MAO-B. They are derived from distinct genes and differ in their substrate 
specificity and cellular localization. Both MAO-A and MAO-B have similar affinities for 
dopamine 
 DOPAC diffuses out of nerve terminals and is extraneuronally converted to 
homovanillic acid (HVA) by catechol-O-methyltransferase (COMT; Figure 2.2). Also, 
extracellular DA that escapes dopamine uptake is converted to 3-methoxytyramine (3-MT) 
by COMT in glial cells or postsynaptic neurons. In addition, part of HVA is derived from 
3-MT in a reaction catalyzed by MAO (Figure 2.2). Tissue levels of 3-MT can be used as 
index of dopamine release, provided that postmortem activity of COMT is inhibited, 
whereas most HVA is derived from DOPAC, and is considered as a ’second metabolite’ 
rather than a marker of extra-neuronal activity (Westerink, 1985). The role of COMT in 
clearance of extracellular DA is minor in areas with high DA uptake such as the striatum. 
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Figure 2.2. Dopamine (DA) synthesis and metabolism pathways. TH (tyrosine hydroxylase), 
DOPA (3,4-dihydroxyphenylalanine), AAADC (aromatic amino acid decarboxylase), VMAT2 
(vesicular monoamine transporter 2), DAT (dopamine transporter), MAO-A and MAO-B 
(monoamine oxidase types A and B), DOPAC (3,4-dihydroxyphenylacetic acid),COMT (catechol-
O-methyltransferase), HVA (homovanillic acid), 3-MT (3-methoxytyramine).   
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2.1.2 DA release and uptake 
When an action potential arrives at the nerve terminal, DA is released from synaptic 
vesicles via Ca2+-dependent exocytotic release. However, Ca2+-independent release has 
also been reported. The main point of release of DA from axon terminal is represented by 
regular enlargements of the axon called axonal varicosities. Released DA can diffuse 
beyond synaptic cleft to reach targets far from the release site (volume transmission;  
reviewed by Zoli et al., 1998; Rice and Cragg, 2008).  
Dopamine neurons display three main patterns of activity: an inactive, hyperpolarized 
state; a slow (2-10 Hz) single-spike firing and burst firing (15-30 Hz) (reviewed by Grace 
and Bunney, 1984a, b). Single-spike firing is driven by an intrinsic pacemaker potential 
(Grace and Bunney, 1983). Tonic DA transmission, resulting from single-spike firing, has 
been shown to underlie the basal, extrasynaptic DA concentration (e.g. 10-20 nM DA 
found within the striatum), which is mediated by an escape of DA from synapses 
(Floresco et al., 2003). Tonic DA transmission exhibits a slow time course of change and 
is under strong homeostatic control since it is maintained at basal levels even when up to 
80% of the tissue DA levels are depleted (Abercrombie et al., 1990; Castaneda et al., 
1990). In contrast, burst firing of DA neurons is thought to mediate phasic DA 
transmission and induces a high amplitude signal. In this case, intrasynaptic DA 
concentrations reach a low millimolar range (Grace et al., 2007). This high concentration 
of DA release is restricted both spatially and temporally by powerful, immediate reuptake 
into presynaptic terminals (Grace et al., 2007).  Burst firing is activated by behaviorally 
meaningful stimuli and is believed to signal important events to postsynaptic neurons. 
Tonic extracellular DA is usually measured by microdialysis, a neurochemical technique 
that offers high sensitivity and a long timescale. On the other hand, phasic extracellular 
dopamine can be measured by in vivo voltammetry, which has subsecond temporal 
resolution and is most often used in combination with electrical stimulations to probe the 
effects of drugs on DA release and uptake (reviewed by Robinson et al., 2003).  
As already mentioned, following release, DA is rapidly taken up by the dopamine 
transporter (DAT) into the presynaptic DA terminals (Sotnikova et al., 2006).  Plasma 
membrane DAT is the most important and highly efficient mechanism controlling 
functional extracellular DA concentrations in the dorsal and ventral striatum (Benoit-
Marand et al., 2000). DAT is localized in the soma, dendrites, axons and axon terminals of 
DA midbrain neurons (Nirenberg et al., 1996). Ultrastructural immunohistochemical 
studies have demonstrated that DAT is mostly present extrasynaptically (Nirenberg et al., 
1996), supporting the idea of extrasynaptic DA transmission. DAT is a major target of 
psychostimulant drugs, such as cocaine, which induces dramatic increase in extracellular 
DA concentrations by interfering with DAT function. Also, the selectivity of neurotoxins 
such as 6-OHDA and MPTP for DAergic neurons depends on their high affinity for DAT 
(Gainetdinov et al., 1997; Takahashi et al., 1997) 
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2.1.3 DA receptors 
Various actions of DA are mediated by five distinct subtypes of G protein-coupled 
receptors. On the basis of their pharmacology and coupling to adenylyl cyclase, the 
dopamine receptors are classified into two populations: D1-like receptors, which stimulate 
adenylyl cyclase and D2-like receptors which inhibit adenylyl cyclase (Jaber et al., 1996). 
The D1-like DA receptor population includes D1 and D5 receptors and the D2-like 
receptor population includes D2, D3 and D4 receptors. D1 and D2 receptors are involved 
in the reinforcing properties of different drugs of abuse, control of locomotion as well as 
in the mediation of the effects of DA on learning and memory. D1 receptors are the most 
widely expressed DA receptors in the brain, with the highest level of expression in the 
projection areas of midbrain DA neurons. In the striatum, D1 receptors are expressed on 
the spiny dendrites and perikarya of medium spiny neurons that are part of the direct 
pathway of basal ganglia. Also, D1 receptors are found on the axons of striatonigral 
pathway and both axons and terminals in the SNpr and entopeduncular nucleus (Yung et 
al., 1995). D2 receptors are found in the olfactory tubercle, nucleus accumbens and in the 
medium spiny GABA neurons of the striatum that are part of the indirect pathway of the 
basal ganglia. It should be emphasized that this segregation in the expression of D1 and 
D2 receptors in the striatum is not exclusive, and many neurons that predominantly 
express one type of the receptor may also express small amounts of the other receptor 
subtype (Aizman et al., 2000). Interestingly, two recent studies demonstrated the existence 
of a complete segregation between the D1- and D2-receptor-expressing striatal neurons in 
response to pharmacological stimuli (Bateup et al., 2008; Bertran-Gonzalez et al., 2008).  
Part of the D2 receptors that are found in striatum, substantia nigra pars compacta and 
ventral tegmental area are expressed by the dopaminergic neurons themselves. These 
dopaminergic D2 receptors serve as autoreceptors and have an important role in the 
regulation of presynaptic function in a feedback-inhibitory manner (Jaber et al., 1996; 
Missale et al., 1998). D2 autoreceptors are localized on the soma, dendrites and nerve 
terminals. Activation of the somatodendritic D2 receptors slows the firing rate of DA 
neurons, while activation of autoreceptors on the nerve terminals inhibits dopamine 
synthesis and release. Thus, D2 receptors can be defined as synthesis-regulating, release-
regulating and impulse-regulating autoreceptors. In addition to inhibition of adenylyl 
cyclase, D2 autoreceptors inhibit DA neurons by activation of inwardly-rectifying K+ 
channels and inhibition of voltage-gated Ca2+ channels (Missale et al., 1998; Schmitz et 
al., 2003). 
2.2 Basal ganglia 
The basal ganglia are a group of subcortical nuclei involved in the control of movement. 
The basal ganglia include the caudate and putamen (striatum in rodents), the external 
segment of globus pallidus (GPe), the internal segment of globus pallidus (GPi; its 
equivalent in rodents is called entopeduncular nucleus), the subthalamic nucleus (STN) 
and substantia nigra pars reticulata (SNpr; Figure 2.1B) (reviewed by Smith et al., 1998b). 
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The striatum is the major division of basal ganglia that receives afferent inputs from 
cerebral cortex, and is a principal site where information processing occurs. More than 
90% of all of the cells in the striatum are GABAergic medium spiny neurons and are 
classified into two subclasses by different neuropeptides and dopamine receptors 
subclasses that they express. The remaining 5-10% of neurons in the striatum are either 
GABAergic or cholinergic interneurons (Tepper and Bolam, 2004). The globus pallidus 
internal segment and substantia nigra pars reticulata are the principal output nuclei of the 
basal ganglia that provide inhibitory (GABAergic) connections to the targets of the basal 
ganglia located in the thalamus and brain stem (those include the ventral tier of thalamus, 
the lateral habenula, the superior colliculus, the mesopontine tegmentum and the reticular 
formation). Target nuclei of basal ganglia send glutamatergic, excitatory projections back 
to the striatum and to the motor cortex, closing the feedback loop (Figure 2.1B).  
Information from the cortex is processed and transmitted to the output nuclei of the 
basal ganglia via two routes: either directly from the striatum to SNpr/GPi or indirectly, in 
a circuit which involves an inhibitory projection from striatum to GPe, an inhibitory 
projection from GPe to STN, and an excitatory projection from STN to the output nuclei 
(Smith et al., 1998a, b). The direct and indirect pathways arise from two different 
populations of medium spiny neurons. Medium spiny neurons that express D1 dopamine 
receptors and contain substance P are part of the direct pathway, while those that contain 
enkephalin and D2 dopamine receptors give rise to the indirect pathway. The activation of 
the direct pathway results in disinhibition of the targets of the basal ganglia, leading to the 
facilitation of the movement, whereas activation of the indirect pathway increases the 
levels of tonic inhibition of the targets of the basal ganglia and leads to the suppression of 
movements (Smith et al., 1998b). An imbalance in the activity of the direct and indirect 
pathways is thought to be the cause of movement disorders such as Parkinson’s and 
Huntington’s disease. Furthermore, pharmacological manipulation or surgical 
interventions that restore the balance between the two pathways alleviate the abnormal 
motor activity. 
The striatum is the most important target of midbrain DA neurons and dopamine 
released there has an important regulatory function in the circuitry of the basal ganglia 
(Figure 2.1B). The nigral neurons provide excitatory inputs mediated by D1 type DAergic 
receptors on the spiny neurons of the direct pathway and inhibitory inputs mediated by D2 
receptors on the spiny neurons that are part of the indirect pathway. Thus, different actions 
of DA in the striatum produce the same effect; that is, a decrease in the inhibitory outflow 
of the basal ganglia and a resultant facilitation of movements. In addition, SNpc DA 
neurons innervate the other basal ganglia nuclei, such as GPi and GPe and STN, and send 
projections to the thalamus affecting directly thalamo-cortical activity. Additionally, 
dendritic DA release in the SN is a mechanism by which nigral DA neurons regulate not 
only their own activity but also facilitate GABA release from the axons of striatonigral 
GABAergic neurons in the SNpr via activation of D1 receptors (Gauthier et al., 1999; 
Smith and Kieval, 2000; Smith and Villalba, 2008). Taken together, DA regulates the 
function of the basal ganglia by acting at multiple sites within the circuitry. 
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2.2.1 Parkinson’s disease 
Parkinson’s disease (PD) is an age-related, progressive neurodegenerative disorder. 
Clinically, PD manifests mainly by impairments of motor function, including resting 
tremor, rigidity, bradykinesia and gait disturbances with postural instability. However, 
with time, PD patients develop nonmotoric impairment such as dementia, depression and 
sleep disturbances (Lang and Lozano, 1998a, b; Olanow, 2004). Pathologically, PD is 
characterized by the progressive death of DAergic neurons in the SNpc and a consequent 
reduction in striatal DA, which accounts for most of the classical motor symptoms of PD. 
There is a quite long presymptomatic period; at the onset of parkinsonian signs, about 70-
80% of striatal DA nerve terminals and about 50-60% of DA cell bodies in SNpc have 
already been lost. However, other neurotransmitter systems, such as noradrenergic, 
serotonergic and cholinergic systems, also degenerate to a lesser extent. This may account 
for the nonmotor symptoms of PD. Another important pathological feature of the disease 
is the presence of intracellular inclusions called Lewy bodies that contain proteins such as 
α-synuclein (Spillantini et al., 1997). The factors thought to trigger neuronal degeneration 
and death in PD include oxidative stress, mitochondrial dysfunction, excitotoxins, 
accumulation of damaged proteins and deficiency of trophic factors (Lotharius and 
Brundin, 2002; Schulz, 2008). Recently discovered PD-associated genes suggest that 
aberrations in ubiquitin–proteasome pathway and cellular stress resulting from 
mitochondrial dysfunction are involved in pathogenesis of PD (Jain et al., 2005). It should 
be noted, however, that familial PD accounts for a small minority of cases (Farrer, 2006).   
2.2.2 Animal models of PD 
To study the pathogenesis of PD and test therapeutic agents for its treatment, animal 
models for PD have been developed. The most commonly used are “classical” PD models 
utilizing toxins that selectively destroy DA neurons, such as the 6-hydroxy-dopamine (6-
OHDA model) and the 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine (MPTP) models 
reviewed by (Schober, 2004). Use of MPTP replicates many of the biochemical and 
neuropathological features of PD. MPTP  easily crosses the blood-brain barrier and is 
converted to MPP+ by MAO-B in glial cells. Thereafter, MPP+ enters DA neurons, where 
it impairs mitochondrial respiration and causes cell death. MPTP is mainly used in non-
human primates and mice, since rats are almost completely insensitive to MPTP-induced 
neurodegeneration (Blum et al., 2001). Also, the level of DA degeneration in this 
paradigm depends on the dose and schedule of MPTP administration (Jackson-Lewis and 
Przedborski, 2007). The 6-OHDA is administered via intracerebral injection and it is taken 
into DA neurons by DAT. The 6-OHDA produces oxidative stress and mitochondrial 
dysfunction, inducing death of DA neurons (Glinka and Youdim, 1995; Blum et al., 2001; 
Ding et al., 2004; Berretta et al., 2005; Hanrott et al., 2006; Tanaka et al., 2006). However, 
both of the neurotoxins fail to replicate progressive degeneration of DA neurons, the 
motor symptoms of PD and generation of Lewy bodies.  
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Recently, the identification of PD-linked genes, such as α-synuclein, DJ-1, LRRK2, 
Parkin, UCH-L1 and PINK1, led to the creation of transgenic and knockout models of the 
disease in rodents (Devine and Lewis, 2008). These transgenic animal models are useful 
for understanding the cause and mechanisms of PD as they replicate many key features of 
the disease, including selective neurodegeneration, neurochemical deficits, Lewy body 
neuropathology and motor deficits.  
Treatment of PD is symptomatic, with substitution therapy with dopaminergic drugs 
(levodopa, DA agonists and MAO inhibitors) as the main option for alleviating motor 
symptoms (Olanow, 2004; Schapira, 2009). Thus, the goal of current research, especially 
in the field of neurotrophic factors, is to find agents that can stop/slow progression of PD 
or reverse neurodegeneration.  
2.3 Neurotrophic factors 
‘Neurotrophic factor’ is a term generally applied to the naturally occurring polypeptides 
that support the survival and development of neurons. Neurotrophic factors are secreted 
molecules that produce their effects by activation of specific receptors on the cell surface. 
The first neurotrophic factor, nerve growth factor (NGF), was identified more than 50 
years ago (Levi-Montalcini, 1987). The early studies with NGF were conducted in the 
peripheral nervous system and revealed that NGF is synthesized and secreted by the target 
organs of the nerves, taken up by the nerve terminals and then retrogradely transported to 
the cell bodies. Only neurons that received NGF signal from their targets kept connections 
with the target and survived. These findings lead to creation of the neurotrophic 
hypothesis, according to which neurons are born in excessive numbers during 
development (Burek and Oppenheim, 1996) and in order to survive and to establish 
appropriate connections developing neurons must compete for a limiting amount of 
neurotrophic factor derived from the target tissue (Lewin and Barde, 1996). The target-
derived neurotrophic factor pattern appears to predominate in the peripheral system. In the 
central nervous system, in addition to being target-derived, neurotrophic factors are 
released from glia or neurons and may act on neighboring neurons in the absence of 
synaptic connections (paracrine mode) as well as on the very neurons that release them 
(autocrine mode; (Bothwell, 1995). In addition to being transported retrogradely, 
neurotrophic factors are anterogradely transported to axon terminals, where they are 
secreted and act on the cell bodies or nerve terminals of other nerves (Lewin and Barde, 
1996; Nestler et al., 2001).  
Most neurotrophic factors seem to have broader roles than were originally postulated. 
Thus, in addition to regulation of developmental survival, the principal roles of 
neurotrophic factors in the developing CNS include biochemical and morphological 
differentiation, stimulation of axonal growth and synaptogenesis. In the adult nervous 
system, neurotrophic factors are involved in the maintenance of target innervations and 
cell survival, as well as in the regulation of synaptic plasticity (Hefti, 1997; Sariola and 
Saarma, 2003). Also, several neurotrophic factors that act through different signaling 
pathways can provide trophic support to the same neuronal population. Growth factors and 
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their signaling proteins thus represent potential drug targets for the treatment of 
neurological diseases in which neuronal function is diminished or disturbed, e.g. in 
Alzheimer’s disease, PD, amyotrophic lateral sclerosis (ALS), Huntington’s disease, 
addiction, and depression. The traditional neurotrophic factors belong to families of 
structurally and functionally related molecules, which include neurotrophins (NGF, brain 
derived neurotrophic factor (BDNF), neurotrophin-3 (NT-3) and neurotrophin-4 (NT-4), 
(Huang and Reichardt, 2001)), glial cell-line derived neurotrophic family ligands (GFLs) 
(Baloh et al., 2000; Airaksinen and Saarma, 2002), neurokines (Sariola et al., 1994) and 
the MANF/CDNF family of neurotrophic factors (mesencephalic astrocyte-derived 
neurotrophic factor/conserved dopaminergic neurotrophic factor) (Petrova et al., 2003; 
Lindholm et al., 2007).  
2.4 The GDNF family of neurotrophic factors 
GDNF (glial cell-line derived neurotrophic factor) was originally purified from a rat 
glioma cell-line, and was characterized as a glycosylated, disulfide-bonded homodimer 
that enhanced survival and morphological differentiation of midbrain DAergic neurons 
(Lin et al., 1993). GDNF and the subsequently discovered, structurally related factors 
neurturin (NRTN), persephin (PSPN) and artemin (ARTN), comprise the GDNF family of 
neurotrophic factors (Lin et al., 1993; Kotzbauer et al., 1996; Baloh et al., 1998; Milbrandt 
et al., 1998; Baloh et al., 2000; Airaksinen and Saarma, 2002). In spite of low sequence 
homology, GFLs represent a distinct subclass within the transforming growth factor-β 
superfamily because they, like the other TGF-β family members, have seven conserved 
cysteines with similar spacing, and contain three disulfide bonds arranged in a typical 
configuration known as ‘cysteine knot’ (reviewed by Airaksinen and Saarma, 2002). GFLs 
are synthesized as pre-proGFLs and then processed to mature proteins upon secretion or 
extracellularly after secretion. 
Because of the powerful neurotrophic effects it has on DA neurons, GDNF has raised 
interest as a potential therapeutic agent for the treatment of PD. In addition to DA neurons, 
GDNF has been shown to promote survival of wide variety of neurons. In the central 
nervous system, GDNF promotes survival of spinal and central motor neurons (Henderson 
et al., 1994; Oppenheim et al., 1995; Yan et al., 1995), basal forebrain cholinergic neurons 
(Williams et al., 1996), central noradrenergic neurons (Arenas et al., 1995) and cerebellar 
Purkinje cells (Mount et al., 1995). Furthermore, GDNF supports sympathetic, 
parasympathetic, enteric and peripheral sensory neurons (Baloh et al., 2000; Airaksinen 
and Saarma, 2002). Likewise, NRTN and ARTN promote the survival of several neuronal 
populations. NRTN was discovered as a survival factor for sympathetic neurons 
(Kotzbauer et al., 1996). It is also able to support survival of DA neurons in vitro and it 
can effectively regenerate DA neurons in vivo (Horger et al., 1998; Åkerud et al., 1999, 
reviewed by Chiocco et al., 2007). However, unlike GDNF it does not induce axonal 
growth or hypertrophy. PSPN protects the brain from ischemic insults (Tomac et al., 
2002), and has been demonstrated to support the survival of midbrain DA neurons 
(Milbrandt et al., 1998) in vitro as well as preventing the loss of DA neurons in a mouse 
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model of PD (Akerud et al., 2002). However, PSPN does not support peripheral neurons 
(Milbrandt et al., 1998). ARTN, the most distant member of the family, can support the 
survival of sensory neurons and sympathetic neurons both in vitro and in vivo, and 
supports DA neurons in vitro, although its expression in human brain is very low (Baloh et 
al., 1998). Outside of the nervous system, GDNF has been found to regulate 
morphogenesis of ureteric branching (Moore et al., 1996; Pichel et al., 1996; Sanchez et 
al., 1996) and spermatogenesis (Meng et al., 2000). 
2.4.1 The GDNF family signaling 
GFRα receptors All GDNF family members signal through a common signaling receptor, 
the Ret tyrosine kinase, but first they bind to one of the glycosyl phophatidylinositol 
(GPI)-linked GDNF family co-receptors α (GFRα1-4; Airaksinen et al., 1999). GDNF 
primarily binds to GFRα1, NRTN to GFRα2, ARTN to GFRα3 and PSPN to GFRα4, 
although there is a certain amount of promiscuity in ligand binding. The original model of 
GFL signaling proposed stepwise formation of a GFL-receptor complex. Thus, GDNF, a 
homodimer, complexes with either a monomeric or dimeric GFRα1 co-receptor. Next, this 
ligand-co-receptor complex brings two Ret transmembrane molecules together, which 
leads to trans-autophosphorylation of specific tyrosine residues and the induction of 
intracellular signaling (Jing et al., 1996; Sariola and Saarma, 2003).  
 
Ret (rearranged during transfection) was considered an orphan, oncogenic receptor 
tyrosine kinase (Takahashi and Cooper, 1987) until its physiological role as a signaling 
receptor for GFLs was uncovered (Durbec et al., 1996; Treanor et al., 1996; Trupp et al., 
1996). The Ret receptor consists of an extracellular part with four cadherin-like domains 
and a cysteine-rich region important for GFL/GFRα binding, a transmembrane part, and 
an intracellular part containing a tyrosine kinase domain and a C-terminus that have a 
function in the activation of downstream signaling pathways (Figure 2.3; Runeberg-Roos 
and Saarma, 2007). There are two major splice variants of Ret protein that differ from 
each other in the length of the C-terminus tail: a short isoform with 9 amino acids (Ret9) 
and a long isoform containing 51 amino acids (Ret51). The Ret9 isoform contains 14 
tyrosine residues whereas Ret51 possesses two additional tyrosines within this 51 amino 
acid stretch. There are indications that the two isoforms might fulfill different biological 
functions; Ret9 may be important for enteric innervation and renal development while 
Ret51 is required for growth and metabolism of mature sympathetic neurons (de Graaff et 
al., 2001; Tsui-Pierchala et al., 2002; Runeberg-Roos and Saarma, 2007).  
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Figure 2.3. Schematic drawing of the Ret protein containing four cadherin-like domains (CLD), a 
cysteine-rich domain (CRD), a transmembrane domain (TMD), juxtamembrane domain (JMD) 
and an intracellular tyrosine kinase (TK). Also, the two alternatively spliced forms, RET9 and 
RET51, are indicated. Ret is stimulated by complexes of GFL with GPI-anchored GFRα co-
receptors that are distributed within lipid rafts. The signaling pathways triggered upon Ret 
activation are indicated. These include the phosphoinositide 3-kinase (PI3K)/AKT pathway, 
mitogen activated protein kinase pathway (MAPK), Src-family kinase and phospholipase Cγ 
(PLCγ).  Modified from (Santoro et al., 2004). 
Ret receptor activation leads to the phosphorylation of the key tyrosine residues such as 
Tyr905, Tyr981, Tyr1015, Tyr1062 and Tyr1096 (only in the long isoform), which function as the 
docking sites for several adaptor proteins (Airaksinen and Saarma, 2002). This then leads 
to activation of downstream signal transduction pathways typical of receptor tyrosine 
kinase signaling (Figure 2.3), including the phosphoinositide 3-kinase (PI3K)/AKT 
pathway, the Jun N-terminal kinase pathway (JNK), the mitogen activated protein kinase 
pathway (MAPK), the Src-family kinases and phospholipase Cγ (PLCγ). These signalling 
pathways regulate cell survival, proliferation, differentiation, migration, neuritogenesis, 
branching morphogenesis and synaptic plasticity (Figure 2.3; Sariola and Saarma, 2003; 
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Santoro et al., 2004; Arighi et al., 2005). For example the MAPK and Src-kinase pathways 
are indicated to be involved in neurite outgrowth and neuronal survival as well as ureteric 
branching (Kaplan and Miller, 2000; Fisher et al., 2001; Sariola and Saarma, 2003). The 
PI3K pathway is crucial for both neuronal survival (Soler et al., 1999) and neurite 
outgrowth (van Weering and Bos, 1998) and is thought to be required for the 
differentiation of dopaminergic neurons (Pong et al., 1998). Accordingly, it has been 
demonstrated that the constitutively active form of Akt has pronounced trophic effects on 
DA neurons in mice, including increases in neuronal size, phenotypic markers and 
sprouting, and that it provides protection to DA neurons against neurotoxic insults in vivo 
(Ries et al., 2006). Recently, in vivo data from knock-in animals bearing targeted 
mutations of the key tyrosine residues as well as the serine 697 residue in the Ret tyrosine 
kinase domain clarified the roles of different Ret signaling pathways (Asai et al., 2006; 
Encinas et al., 2008). 
2.4.2 Ret-independent signaling pathways 
Ample evidence suggests that GDNF signaling is more complex than it was initially 
proposed to be, and co-operation of the neurotrophin with other proteins has been reported 
(shown in figure 2.4). 
GFRα1 Although both GFRα1 and Ret can mediate GDNF signaling, their expression 
patterns in the CNS do not completely overlap (Trupp et al., 1997; Yu et al., 1998). The 
expression of GFRα1 in cells lacking Ret suggested an alternative role for this protein 
beyond being a co-receptor for Ret. Furthermore, this finding suggested that GDNF may 
signal independently of Ret, presumably in collaboration with novel transmembrane 
proteins. Firstly, it has been shown that GFRα1 can modulate Ret signaling in non-cell-
autonomous fashion (trans signaling; Paratcha et al., 2001). Additionally, in cells that do 
not express Ret, GDNF via GFRα1 can activate Src-family kinases, which further leads to 
phosphorylation of ERK/MAPK and PLC-γ, activation of the transcription factor CREB 
and the induction of Fos (Poteryaev et al., 1999; Trupp et al., 1999).  
Met receptor tyrosine kinase In a cell line lacking endogenous Ret, GDNF/GFRα1 
was found to activate Met receptor tyrosine kinase via Src-family kinases (Popsueva et al., 
2003). However, the in vivo significance of GDNF/Met signaling is still unclear. The 
finding that the phenotypes of GDNF and GFRα1 knockout mice were similar to that of 
Ret knockout mice, and that all die at birth (Baloh et al., 2000), suggested that Ret-
independent signaling via GFRα1 may play a role in neuronal functions postnatally rather 
than during embryogenesis. 
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Figure 2.4. Ret-independent signaling of GDNF. The GDNF-GFRα1 complex binds to neural cell 
adhesion molecule (NCAM) and induces signaling and activation of Fyn kinase, and via Src 
kinase activation further activates Met receptor tyrosine kinase. Modified from (Santoro et al., 
2004). 
NCAM The neural cell adhesion molecule (NCAM), a prominent cell adhesion 
molecule, was found to be widely co-expressed with GFRα receptors, including the cells 
that do not express Ret (Crossin and Krushel, 2000). The fact that in the non-Ret 
expressing cell lines, the intracellular pathways of the GDNF signaling were strikingly 
similar to those triggered by NCAM prompted researchers to examine the role of NCAM 
in GDNF signaling. Paratcha et al (2003) discovered that, in the presence of GFRα1, 
GDNF binds with high affinity to NCAM and causes activation of the tyrosine kinase Fyn 
and focal adhesion kinase (FAK) in the cytoplasm in a Ret-independent fashion. GDNF, 
through NCAM, stimulates Schwann cell migration and differentiation as well as axonal 
growth in primary hippocampal and cortical neurons (Paratcha et al., 2003; Iwase et al., 
2005). Furthermore, NCAM-deficient mice, otherwise viable and fertile, have 
impairments in spatial learning (Cremer et al., 1994) and heterozygous GDNF knockout 
mice exhibited a similar phenotype (Gerlai et al., 2001). These findings suggested that 
GDNF/GFRα1/NCAM signaling indeed has physiological relevance in vivo.  Even before 
NCAM was suggested as a signaling receptor for GDNF, Chao and colleagues observed 
that NCAM function-blocking antibodies antagonized the effects of GDNF both on 
survival and outgrowth of DA neurons derived from normal adult rats (Chao et al., 2003). 
However, most of the data on GDNF/GFRα1/NCAM signaling were obtained in vitro. 
When Enomoto and colleagues (2004) studied the physiological relevance of Ret-
independent GDNF/GFRα1 signaling in mutant mice that expressed GFRα1 only in Ret 
 
 
 
 
16 
bearing cells, and thus lack trans GFRα1, they found no structural abnormalities in the 
peripheral nervous system, the central nervous system or the kidney in these so-called cis 
only mice (Enomoto et al., 2004). Thus, this study suggested that Ret-independent GFRα1 
signaling appears to play only a minor role in organogenesis and nerve regeneration in 
vivo. However, a recent in vivo study showed that NCAM is indeed involved in mediating 
the effects of GDNF on neurite outgrowth in lesioned DA neurons (Cao et al., 2008). 
Interestingly, GDNF was shown to regulate morphological differentiation and tangential 
migration of GABAergic cells in the cortex via GFRα1, but neither Ret nor NCAM 
appeared to be important in this process, suggesting the existence of an additional 
transmembrane signaling receptor for this factor (Pozas and Ibanez, 2005). 
2.4.3 Cooperation of GDNF with other proteins 
TGF-β (transforming growth factor-β) It has been shown that GDNF exerts its trophic 
activity on a variety of cultured neurons, including DA neurons, only in the presence of 
cooperating TGF-β factor (Krieglstein et al., 1998). TGF-β is believed to be involved in 
the clustering of GFRα1 at the cell membrane, which may help  the ligand to recognize the 
co-receptors (Peterziel et al., 2002). Also, the importance of cooperation between GDNF 
and TGF-β has been confirmed in a mouse model of PD, where it was shown that TGF-β 
is essential for the neuroprotective effects of exogenous GDNF (Schober et al., 2007). A 
recent study reported a normal number of midbrain TH-positive neurons in TGF-
β2/GDNF double mutant mice at embryonic day 18.5, indicating that cooperation of 
GDNF and TGF-β2 is not essential for development of DAergic neurons (Rahhal et al., 
2009).  
Heparan sulfate Cell-surface associated heparan sulfate glycosaminoglycans are required 
for GDNF to activate Ret and induce axonogenesis in neurons (Barnett et al., 2002). 
Interestingly, the effect of a rather non-specific chemical deprivation of heparan sulfate 
from kidneys is similar to that of genetically deleting GDNF and Ret (Bullock et al., 
1998). It was proposed that heparan sulfate may modulate GDNF signaling by 
concentrating the ligand (Barnett et al., 2002).  
2.4.4 Ret as an oncogenic protein 
Beside its role as a growth factor receptor, Ret can function as an oncogenic protein when 
mutated. Mutations resulting in Ret receptor dysfunction cause Hirschprung’s disease, 
which is characterized by megacolon agangliosis. In contrast, missense mutations leading 
to constitutive activation of Ret give rise to multiple endocrine neoplasia types 2A and 2B 
and familial medullary thyroid carcinoma (FMTC) (reviewed by Manie et al., 2001). 
MEN2A and MEN2B are autosomal dominant cancer syndromes characterized by 
medullary thyroid carcinoma and pheochromocytoma. MEN2A patients additionally 
suffer from hyperparathyroidism while MEN2B patients, on the other hand, develop more 
aggressive and complex phenotype including developmental abnormalities such as 
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marfanoid habitus, thickened corneal nerve and ganglioneuromatosis of the 
gastrointestinal tract and mucosa (reviewed by Takahashi, 2001). FMTC is characterized 
by medullary thyroid carcinoma only. Also, papillary thyroid carcinoma (PTC), associated 
with genomic rearrangements in the Ret gene, is caused by Ret activation. In MEN2A and 
FMTC patients, several germline missense mutations that induce disulfide-linked 
homodimerization and activation of the Ret receptor are found in the cysteine-rich 
extracellular domain.  
More than 95% of MEN2B cases are caused by a single germline mutation that results 
in a substitution of threonine for the normal methionine at codon 918 (Met918Thr) in the 
Ret kinase domain (Eng et al., 1996). The Met918Thr mutation has been predicted to 
induce a conformational change of the tyrosine kinase catalytic core, leading to activation 
of Ret in a monomeric form in a ligand-independent manner (Eng et al., 1996). However, 
it was subsequently shown that ligand can still induce dimerization of the MEN2B Ret and 
additionally increase the activity of the mutated receptor (Bongarzone et al., 1998). Initial 
reports suggested that the MEN2B mutation alters phosphorylation and the substrate 
specificity of Ret so that it preferentially binds substrates of cytoplasmic kinases that 
would lead to activation of signaling pathways distinct from Wt Ret pathways (Santoro et 
al., 1995; Songyang et al., 1995; Liu et al., 1996; Bocciardi et al., 1997). However, most 
of these studies compared downstream signaling pathways of the MEN2B Ret with those 
of the Wt, inactive Ret (in the absence of ligand activation). Gujral and co-workers 
showed that under stimulation with GDNF, there was no difference in the nature of Wt 
and MEN2B Ret substrates and that Met918Thr mutation leads to an increase in the 
intrinsic kinase activity of Ret, as well as ligand-independent dimerization and 
autophosphorylation (Gujral et al., 2006). Also, although it was reported that MEN2B Ret 
precursor is active already in the endoplasmic reticulum before reaching the cell surface, 
no qualitative differences in the signaling between Wt and MEN2B Ret were observed 
(Runeberg-Roos et al., 2007). Nevertheless, some alterations in the signaling properties of 
the MEN2B Ret receptor cannot be completely ruled out. 
2.4.5 GDNF, GFRα1 and Ret distribution in the CNS 
Using in situ hybridization and reverse transcription-PCR, GDNF mRNA was localized in 
many different regions of the developing and adult brain, including the striatum, nucleus 
accumbens, globus pallidus, olfactory tubercle, hippocampus, granular layer of 
cerebellum, parietal and piriform cortices, thalamus and olfactory bulb (Schaar et al., 
1993; Springer et al., 1994; Choi-Lundberg and Bohn, 1995; Nosrat et al., 1997). The 
expression of GDNF mRNA in the targets of DA neurons in the SNpc is accordant with its 
role of a target-derived neurotrophic factor for these neurons. In fact, when injected into 
the rat striatum, GDNF is retrogradely transported to the dopaminergic cell bodies in the 
SNpc (Tomac et al., 1995). Reports on the expression of GDNF mRNA in the SN are 
somewhat controversial. While some studies did not detect GDNF mRNA in the SNpc 
(Nosrat et al., 1997), others reported the presence of GDNF mRNA in the SN and 
suggested an autocrine and paracrine role for GDNF (Golden et al., 1998; Cho et al., 2004; 
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Oo et al., 2005). On the other hand, it has been shown that only the GDNF protein without 
mRNA expression, is found in the rostromedial part of the SN and the VTA in the adult 
rat (Barroso-Chinea et al., 2005). Furthermore, the same group has demonstrated that 
under physiological conditions, and not only after being injected or overexpressed, GDNF 
is retrogradely transported from the striatum to the ventral midbrain.  
During development, GDNF mRNA expression in the rat striatum was first detected 
around E15 (Nosrat et al., 1997). During subsequent days of prenatal development, levels 
of GDNF mRNA expression increase, reaching their highest levels during early postnatal 
life and peaking at postnatal day 0 (P0) and  postnatal days 10-14 (Schaar et al., 1993; 
Stromberg et al., 1993; Choi-Lundberg and Bohn, 1995; Nosrat et al., 1997). Likewise, 
protein levels of GDNF in the striatum are highest during the first postnatal week; 
thereafter, levels of GDNF decrease in the striatum of the adult rat (Lopez-Martin et al., 
1999; Oo et al., 2005). The greatest GDNF expression in the striatum coincides with a 
developmental period of natural cell death of DAergic neurons and suggests a crucial role 
for GDNF in this event. Oo and colleagues (Oo et al., 2005) demonstrated that medium-
sized neurons in the developing striatum express GDNF mRNA and confirmed previous 
findings that GDNF protein is localized in the striatal neuropil (Lopez-Martin et al., 1999). 
In addition, several groups found GDNF protein in fibers and axons in the principal 
striatal efferent targets, including SNpr, GP and the endopeduncular nucleus (Kawamoto 
et al., 2000; Oo et al., 2005).  This is in line with studies reporting the anterograde 
transport of GDNF along neuronal projections, from the striatum to SNpr and the globus 
pallidus (Kordower et al., 2000; Georgievska et al., 2004). However, in the dorsal striatum 
of an adult rat and in the human caudate putamen (CPu), most of the GDNF-positive cells 
were identified as interneurons (Bizon et al., 1999; Kawamoto et al., 2000). 
The widespread expression of GDNF is consistent with previous findings that GDNF 
supports multiple neuronal populations in addition to its known effects on nigrostriatal 
DAergic neurons. Thus, the cortex and hippocampus, which express GDNF mRNA, may 
serve as sources of GDNF for a number of neuronal populations projecting to these areas. 
For example, cell bodies of the noradrenergic neurons that reside in the locus coeruleus 
and project to the cortex and hippocampus express both GFRα1 and Ret (Trupp et al., 
1997; Glazner et al., 1998). Intriguingly, some GDNF mRNA expression was detected in 
the locus coeruleus during prenatal development, but it was lost by birth (Nosrat et al., 
1997).  
Ret mRNA is often accompanied by GFRα1 receptor mRNA in brain tissues such as 
the SN, dorsal raphe nucleus, locus coeruleus, hypothalamic nuclei, Purkinje and 
molecular layers of cerebellum and brainstem nuclei that innervate skeletal muscles 
(Trupp et al., 1997; Golden et al., 1998; Yu et al., 1998). Thus, it is likely that in these 
areas, GDNF and GFRα1 activate Ret in the cis mode. Expression of both receptors has 
been shown to be predominantly neuronal (Golden et al., 1998). Ret protein is present on 
perikarya and proximal dendrites of DA neurons of the SN (pars compacta, 
predominantly) and VTA (Nosrat et al., 1997; He et al., 2008), and is also found in the 
striatum, on axonal projections of DAergic neurons (Jain personal communication, Hirata 
and Kiuchi, 2007). No Ret mRNA was found in DAergic neuronal target areas (Nosrat et 
al., 1997). However, GFRα1 protein and mRNA are found both in the ventral midbrain 
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and in the striatum (Bresjanac and Antauer, 2000; Cho et al., 2004). The role of GFRα1 in 
the striatum is not known, although in theory, it could act in trans to regulate development 
of the nigrostriatal projections. As mentioned earlier, expression of GFRα1 in rodent brain 
was found to be more widespread than that of Ret (Trupp et al., 1997; Glazner et al., 
1998). Thus, GFRα1 is found in areas such as hippocampus, cortex and medial habenula 
that contain no or very little Ret, but are the targets of systems abundant in Ret, which 
further suggests activation of Ret in trans (Yu et al., 1998). Additionally, this discrepancy 
in expression patterns suggests the existence of alternative signaling receptors for GDNF 
or an alternative role for GFRα1 in addition to being a co-receptor for GDNF. A recent 
study implicated a role for GFRα1 in establishing precise synaptic contacts and inducing 
presynaptic differentiation (Ledda, 2007). 
2.5 GDNF/Ret and the brain DAergic system 
2.5.1 Physiological role of GDNF/Ret signaling in the nigrostriatal DA 
system  
During embryogenesis, neurons are created in excess numbers and undergo a period of 
natural, apoptotic cell death that determines their final number (reviewed by Burke, 2004). 
In rats, cell death can be detected in the SN just before birth, peaks on postnatal days 2 and 
14 (the so-called first and second phase of ontogenic cell death, respectively), and ceases 
on postnatal day 28. Much evidence indicates that these death events are most likely 
regulated by secretion of a limited amount of neurotrophic factors, for which developing 
neurons compete, from target tissues (Burke, 2004). The GDNF, GFRα1 and Ret knockout 
mice, which die at birth due to kidney agenesis, show no reduction in the number of DA 
neurons in the ventral midbrain (Moore et al., 1996; Pichel et al., 1996; Sanchez et al., 
1996; Enomoto et al., 1998). Also, we have found that brain tissue DA levels are similar 
among GDNF-/-, GDNF +/- and GDNF +/+ mice at embryonic day 18 (E18) (Mijatovic 
et. al, unpublished). This indicates that GDNF/GFRα1/Ret signaling is not important for 
fetal development of DA neurons. Alternatively, compensatory modifications may have 
occurred during development, masking the role of GDNF-Ret signaling.  
Nevertheless, the expression of GDNF in a target tissue of DA neurons, its 
developmental regulation and retrograde transport to SN suggest that GDNF may serve as 
physiological, limiting target-derived factor for DA neurons throughout the natural cell 
death period. Indeed, Granholm and colleagues found that GDNF is essential for postnatal 
survival of midbrain DA neurons by grafting fetal neuronal tissue from GDNF knockout 
mice into the brain of wildtype mice (Granholm et al., 2000). Also, it was shown that 
during postnatal development, exogenously provided GDNF diminished natural cell death 
by inhibiting apoptosis while neutralizing antibodies against GDNF augmented it (Burke 
et al., 1998; Burke, 2006). The effects of GDNF appeared to be restricted to the early 
postnatal development of nigral DAergic neurons, more precisely to the first phase of cell 
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death (Beck et al., 1996; Oo et al., 2003). Thus, a transgenic mouse model in which 
overexpression of GDNF was sustained in the striatum throughout development  showed 
an increased number of DA neurons surviving the first phase of natural cell death 
(Kholodilov et al., 2004). However, this increase in the number of DA neurons did not 
persist into adulthood, suggesting that neurotrophic factors other than GDNF also act to 
regulate the number of the DA neurons in the mature SN.   
Heterozygous GDNF knockout mice are viable and by appearance similar to their 
wild-type littermates. Thus, they were used to study the effects of chronic reduction of 
GDNF levels (by 35-50%) in maturation and aging of the nigrostriatal DAergic system 
(Gerlai et al., 2001; Airavaara et al., 2004; Boger et al., 2006). In young adult mice, the 
number of TH-positive cells in the nigra, tissue concentration of DA in the striatum as 
well as TH and DAT levels in the striatum were normal, suggesting that GDNF may not 
be critical for the development and function of the nigrostriatal DAergic system (Gerlai et 
al., 2001; Airavaara et al., 2006); Mijatovic et al., unpublished). However, Airavaara and 
colleagues reported increased striatal extracellular DA levels as well as postsynaptic 
activity in GDNF +/- mice, suggesting that there may have been compensatory alterations 
in their DA system (Airavaara et al., 2004). A deficiency in GDNF was reported to be 
associated with an accelerated decline in motor activity and a decrease in TH 
immunostaining in SN during the aging process (Boger et al., 2006) as well as an 
increased susceptibility to methamphetamine-induced neurotoxicity (Boger et al., 2007). 
Similarly, reduction of GFRα1 co-receptor in heterozygous GFRα1 knockout mice 
resulted in exacerbation of aging-related decline in function of the DAergic system and an 
increased sensitivity to neurotoxins (Boger et al., 2008; Zaman et al., 2008). Thus, GDNF 
appears to be involved in the long-term maintenance of the nigrostriatal DAergic system. 
To investigate the postnatal, physiological role of Ret for the maintenance and function 
of the nigrostriatal DA neurons, conditional Ret knockout mice have been created (Jain et 
al., 2006; Kramer et al., 2007). DAT-Cre-Ret mice contained no Ret in their midbrain DA 
neurons, starting from mid embryonic development. The data obtained from these 
conditional Ret knockouts suggested that Ret is not important for the establishment, 
development and maturation of the nigrostriatal DA system. Aged conditional Ret 
knockout mice, on the other hand, showed loss of midbrain DA neurons, degeneration of 
DA terminals and glial activation in the striatum indicating an important role of Ret in 
long-term maintenance of the nigrostriatal DA system. Also, when MPTP was given to 
conditional Ret knockouts, it was found that physiological Ret signaling is important for 
resprouting of DAergic fiber but its loss did not affect the vulnerability of DA cell bodies 
(Kowsky et al., 2007). However, in spite of the creation of a large number of animal 
models, role of endogenous GDNF-Ret pathway in the postnatal life, maturation and aging 
of brain DA system has not been ascertained. 
Pascual and colleagues recently reported that the deletion of GDNF in 2-month-old 
mice resulted in a marked and progressive reduction of ventral midbrain DA neurons and 
an almost complete ablation of noradrenergic neurons of the locus coeruleus (Pascual et 
al., 2008). These data demonstrated that GDNF is critical for the survival of adult 
catecholaminergic neurons and stress the importance of a continuous neurotrophic support 
for the maintenance of adult neuron survival. The reason for this dramatic discrepancy 
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between previous mouse models with reduced GDNF/GFRα/Ret signaling and the 
conditional GDNF knockout mice is suspected to be related to the timing of the gene 
ablation, compensatory mechanisms independent of GDNF and the existence of 
alternative signaling receptors (Andressoo and Saarma, 2008; Ibanez, 2008).  
2.5.2 Effects of exogenous GDNF on the injured DA system  
Neuroprotection The most robust effect of GDNF in the CNS is the protection of DAergic 
neurons exposed to toxins and other insults. Early experiments with GDNF revealed that  
it promotes survival of DA neurons and protects them against toxin-induced death in vitro 
(Lin et al., 1993). Afterwards, numerous studies further investigating the neuroprotective 
effects of GDNF were performed in animal models of PD, rodents or primates in which 
DAergic neuron degeneration was induced by mechanical insult or by DA neuron-specific 
neurotoxins (with MPTP used in mice and primates, and 6-OHDA in rats). The main 
findings of these studies were that GDNF prevented the loss of nigral DA neurons, the 
decrease of DA nerve terminal density and the depletion of dopamine levels in the 
striatum, as well as lesion-induced motor deficits, if it was administered before or around 
the time of DA neuron injury (Beck et al., 1995; Sauer et al., 1995; Tomac et al., 1995). In 
animal models of PD, GDNF consistently protects DA cell bodies, provided that it is 
delivered at the site of toxic insult in regions such as the striatum, the SN or the lateral 
ventricle, (Beck et al., 1995; Kearns and Gash, 1995; Sauer et al., 1995). In contrast, 
GDNF will  protect DAergic axonal terminals if it is administered in the striatum (Tomac 
et al., 1995; Kirik et al., 2004). Thus, in rats with striatal 6-OHDA lesion, GDNF 
application into the striatum leads to preservation of the entire nigrostriatal pathway 
whereas GDNF administration into SN does not protect DAergic axonal terminals in the 
striatum (Kirik et al., 2000a; Kirik et al., 2000b; Kirik et al., 2004). Furthermore, rescue of 
DA bodies in SN without protection of DAergic striatal innervation, as seen after nigral 
GDNF delivery, is insufficient for the preservation of motor function in rats with striatal 
6-OHDA lesion (Sauer et al., 1995; Winkler et al., 1996; Rosenblad et al., 1999; Kirik et 
al., 2000a, b).  
 
Neurorestoration However, even more important for the treatment of PD are the effects of 
GDNF on dysfunctional neurons that have already started to degenerate. These restorative 
effects have been studied by administering GDNF into an already lesioned, compromised 
nigrostriatal DA system. In these paradigms, GDNF is usually delivered as single or 
repeated bolus injection or continuous infusion into the lateral ventricle, SN or putamen of 
parkinsonian primates or extensively 6-OHDA-lesioned rats. There it restored the 
phenotype of quiescent DA neurons, resulting in increased number and size of TH-
positive cells and TH-positive fiber density in the SN (Hoffer et al., 1994; Gash et al., 
1996; Lapchak et al., 1997a; Gerhardt et al., 1999; Grondin et al., 2002). In addition, 
GDNF treatment elevated tissue levels of DA and its metabolites, enhanced DA turnover 
and stimulated DA release in the SN and GP of MPTP-lesioned monkeys (Gash et al., 
1996; Gerhardt et al., 1999; Gash et al., 2005) or 6-OHDA MFB lesioned rats (Hoffer et 
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al., 1994; Hoffman et al., 1997; Lapchak et al., 1997a). The effects of nigral GDNF 
delivery on recovery of DA function in the striatum were unremarkable(Tomac et al., 
1995; Gash et al., 1996; Gerhardt et al., 1999). On the other hand, GDNF administered 
into the striatum or lateral ventricle of advanced Parkinsonian monkeys was able to 
increase DA levels and DA turnover in the striatum and GP (Grondin 2002). In any case, 
even in the absence of improvement of the striatal DA function in severely-lesioned 
animals, GDNF promoted recovery of toxin-induced motor impairments (Hoffer et al., 
1994; Hoffman et al., 1997; Lapchak et al., 1997b; Gerhardt et al., 1999). It has been 
suggested that GDNF attenuates toxin-induced behavioral impairments by increasing 
DAergic neurotransmission in the SN or by affecting some other system within the basal 
ganglia. Indeed, Xin and colleagues showed that the globus pallidus plays a critical role in 
GDNF-induced functional improvements in PD monkeys (Xin et al., 2008). 
Rats with intrastriatal 6-OHDA lesions provide a model of progressive dopamine 
neuron degeneration and are considered a partial lesion model of PD (Björklund et al., 
1997). In this partial lesion model of PD, ventricular GDNF infusion starting 2 weeks 
postlesion blocked the delayed death of DAergic cells in the SN and improved the motor 
impairments, whereas the striatal GDNF infusion was ineffective. However, both 
administration routes were ineffective in restoring degenerated fiber terminals in the 
striatum (Kirik et al., 2001). On the other hand, Rosenblad and coworkers (1998) showed 
that striatal GDNF delivery leads to axonal sprouting and reinnervation of a partially 
deafferated striatum, and subsequently results in functional recovery of the animals with 
striatal 6-OHDA lesion (Rosenblad et al., 1998). Controversially, the same group showed 
that GDNF induced axonal sprouting, although only around the needle site, that was not 
followed by striatal reinnervation and functional recovery (Rosenblad et al., 2000). Also, 
aberrant sprouting in 6-OHDA lesioned rats was observed near the site of GDNF injection 
(Rosenblad et al., 1999; Kirik et al., 2000a). Likewise, in primate models of PD as well as 
in clinical studies, GDNF was shown to induce sprouting of compromised DA fibers 
(Kordower et al., 2000; Love et al., 2005). In DA neurons of the developing midbrain, as 
well as in mature ventral mesencephalic grafts in oculo , GDNF caused TH-positive fiber 
outgrowth and increased the number of synaptic sites (Lin et al., 1993; Johansson et al., 
1995; Åkerud et al., 1999; Bourque and Trudeau, 2000). All in all, restorative actions of 
GDNF in animal models of PD are not as dramatic as neuroprotective actions. 
2.5.3 Effects of exogenous GDNF on intact DA system  
In the intact nigrostriatal system of rats, a single injection of GDNF into the SN or 
striatum has a direct stimulatory effect on DA neuron function. This so -called 
“pharmacological effect” of GDNF on DAergic neurotransmission includes an increase in 
tissue DA and DA turnover in the ipsilateral SN and striatum, and an increase of striatal 
release of DA and its metabolites (Hudson et al., 1995; Beck et al., 1996; Hebert et al., 
1996; Martin et al., 1996b; Hebert and Gerhardt, 1997; Xu and Dluzen, 2000; Salvatore et 
al., 2004).  Also, acute GDNF has been shown to increase expression of TH (Hudson et 
al., 1995) and/or to augment phosphorylation and activity of TH in the striatum and SN 
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(Salvatore et al., 2004). These neurochemical changes have fully manifested by 1-3 weeks 
after GDNF administration and may persist for up to 6 weeks (Martin et al., 1996b). 
Additionally, a single GDNF injection increases locomotor activity and amphetamine-
induced turning (Hudson et al., 1995; Martin et al., 1996a; Kobayashi et al., 1998). This 
effect of GDNF was blocked by D1 and D2 receptor antagonists (Kobayashi et al., 1998) 
indicating that the improvements in motor behavior induced by GDNF in intact as well as 
in lesioned animals are to a great extent associated with an upregulation of DA function. 
The administration site plays an important role on where in the nigrostriatal DA 
system GDNF exerts its pharmacological actions. Thus, intranigrally administered GDNF 
affected DA function both in the striatum and SN, whereas the stimulatory effects of 
striatally administered GDNF were limited to the striatum. The effects of GDNF on 
nigrostriatal DAergic function may be explained by findings from in vitro studies, which 
found that GDNF increased DA release (Pothos et al., 1998), DA uptake (Lin et al., 1993) 
and enhanced DA neuron excitability by modulating ion channels (Yang et al., 2001; 
Wang et al., 2003). In addition, GDNF augmented TH mRNA and protein levels (Xiao et 
al., 2002) and increased TH phosphorylation and activity in cell cultures (Kobori et al., 
2004). 
However, while continuous long-term GDNF administration to rats with an intact DA 
system initially resulted in an enhancement of the function of the DA system, after 6 
weeks there was a downregulation of TH protein levels in the striatum and of TH mRNA 
in the SN (Rosenblad et al., 2003; Georgievska et al., 2004). This was not accompanied by 
an alteration in other striatal dopaminergic markers, such as DA, VMAT2 and DAT levels, 
and the number of D1- or D2- DA receptors. The TH downregulation was time- and dose- 
dependent and appeared to be a compensatory response to the initial GDNF-induced 
overactivity of DA neurons and its direct effects on TH gene expression. On the other 
hand, in both young and aged intact primates, long-term GDNF administration 
upregulated the function of the DA system (Kordower et al., 2000; Grondin et al., 2003). 
Eslamboli and colleagues showed that in primates, continuous GDNF delivery using viral 
vectors that resulted in the expression of high levels of GDNF upregulated DA 
transmission in the striatum, whereas expression of low levels of GDNF produced only 
minimal effects (Eslamboli et al., 2005). 
2.5.4 GDNF in clinical studies 
The encouraging results in animal models raised hopes that GDNF could be successfully 
used for the treatment of PD. However, in a human clinical study in which GDNF protein 
was delivered at a high concentration into the cerebral ventricles of PD patients, no 
beneficial effects were seen, probably because of the limited penetration to the target brain 
areas, and significant side effects occurred (Nutt et al., 2003).  
In contrast, in two open-label trials of continuous intraputamenal GDNF infusion in 
PD patients, Gill and colleagues reported excellent tolerance, few side effects and clinical 
benefits associated with a significant increase in dopamine storage and fiber sprouting in 
the putamen, as well as an improvement in the motor function of the patients (Gill et al., 
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2003; Love et al., 2005; Slevin et al., 2005). In a randomized, controlled clinical trial 
conducted to confirm the open-label results, however, no significant improvement was 
seen (Lang et al., 2006). It has been suggested that different delivery protocols and dosing 
regimes used in these trials led to different outcomes, and until the methodological 
questions are resolved, it is premature to conclude that GDNF is ineffective as a treatment 
for PD (Sherer et al., 2006).   
Also, in a phase I clinical trial, viral delivery of neurturin resulted in good tolerability 
and safety as well as in mild improvement of parkinsonian symptoms (Marks et al., 2008). 
In a phase II study, even more promising results have been obtained (unpublished, 
Kordower et al., personal communication). 
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3. AIMS OF THE STUDY 
In spite of intensive research, the physiological roles of both GDNF and its signaling 
receptor Ret in the development and maintenance of brain DAergic system remain largely 
unknown. Complicating matters even more, Ret-independent GDNF signaling has recently 
been described. Thus, the purpose of the present study was to elucidate the physiological 
role and significance of GDNF-Ret signaling in the brain DAergic system by using mice 
with constitutively active Ret, MEN2B knock-in mice.  
 
The specific aims of this study were: 
 
1. To investigate whether and how continuous Ret activity affects brain DA 
systems with emphasis on the nigrostriatal system. Thus, we studied 
neurochemical, molecular and behavioral changes in the MEN2B mice. 
2. To characterize in more detail compensatory alterations in the striatal DAergic 
transmission in the MEN2B mice.  
3. To explore whether continuous Ret activity protects the nigrostriatal DAergic 
system against neurotoxins.  
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4. MATERIALS AND MAIN METHODS 
 
A more detailed description of the materials and methods used in the present study is 
given in the respective original publications I-III. 
4.1 Animals 
In the present studies we used homozygous (M/M) and heterozygous (M/+) MEN2B 
knock-in mice and their wild-type (Wt) littermates. The Met918Thr point mutation in 
humans leads to the substitution of normal methionine by threonine at codon 918 in the 
Ret kinase domain resulting in activation of the Ret signaling (Takahashi, 2001). The 
MEN2B mouse model was generated by introducing corresponding mutation, Met919Thr, 
into the murine Ret gene (Smith-Hicks et al., 2000). Therefore, MEN2B mice, that carry 
constitutively active Ret, represent a mouse model for increased Ret signaling. However, 
although not confirmed, difference in the signaling pathways between Wt and MEN2B 
Ret might exist, which needs to be taken into consideration when interpreting the data 
obtained from the MEN2B mice. The MEN2B mice were originally generated on a mixed 
C57BL/6 X 129Sv background (Smith Hicks et al., 2000) and in the Laboratory Animal 
Center, University of Helsinki, the mice were backcrossed on a pure C57BL/6 
background. Male mice were used at 8-16 weeks of age. The mice were housed in groups 
of 2-8 to a cage and had free access to mouse chow and water. They were maintained 
under 12:12 h light/dark cycle with lights on from 06:00 to 18:00 at an ambient 
temperature of 20-22°C. The chief veterinarian of the county administrative board or the 
Committee on Animal Experiments at the University of Helsinki approved all the 
experiments. The experiments were conducted according to the “European Convention for 
the Protection of Vertebrate Animals used for Experimental and other Scientific 
purposes”. The mice were genotyped by conducting a PCR on DNA samples taken from 
the mouse tail (described in more details in Study I). As described by Smith Hicks at al. 
(2002) homozygous M/M mice display an earlier onset and increased severity of C-cell 
and chromaffin cell hyperplasia (that progressed to pheochromocytoma), male 
reproductive defects, ganglioneuromas of adrenal medulla and enlargement of sympathetic 
ganglia, thus more closely matching the human MEN2B syndrome. Heterozygous M/+ 
mice are less severely affected, displaying hyperplasia of thyroid C-cells and adrenal 
chromaffin cells. These abnormalities are minimal at the age of 8-16 weeks when the mice 
were used in our experiments. 
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4.2 Monoamine analysis of brain tissue samples (Studies I, II and 
III) 
The mice were killed by decapitation, their brains rapidly removed from the skull, placed 
on an ice-cooled brain matrix and dissected. The brain dissection method was described in 
details in the Study I. The dissected brain areas include whole striatum, dorsal and ventral 
striatum, hypothalamus, cortex, hippocampus and lower brain stem. The tissue pieces 
were immediately placed into frozen microcentrifuge tubes, weighed and stored at -80°C 
until assayed. Monoamines analyzed from brain tissue samples were DA, DOPAC, HVA, 
5-HT, 5-HIAA, NA, MOPEG (in the Studies I, II and III) and DOPA (in the Study II). 
Monoamine concentrations were determined using HPLC combined with electrochemical 
detector and their concentrations reported in ng/g wet weight of tissue (described in details 
by Airavaara et al., 2005). 
4.3 Immunohistochemistry (Study I and III) 
4.3.1 Tissue preparation 
The mice were anesthetized with sodium pentobarbital (100 mg/kg, i.p.) and perfused 
intracardially with phosphate-buffered saline (PBS) followed by 4% paraformaldehyde in 
0.1 M sodium phosphate buffer, pH 7.4. The brains were removed, postfixed for 4 h and 
stored in sodium phosphate buffer containing 20% sucrose at 4ºC. Coronal striatal and 
nigral sections were cut and saved individually in serial order at -20ºC until used for either 
TH or DAT immunostaining. 
4.3.2 Immunolabelling 
TH immunohistochemistry. Brains from animals of all the genotypes were included in 
every run. In brief, after quenching with 3% hydrogen peroxide and 10% methanol for 5 
min, sections were blocked in blocking buffer (2% normal goat serum (NGS, Chemicon, 
S-1000), 0.3% Triton X-100 in PBS) for 1 h and thereafter incubated in the primary rabbit 
anti-TH antibody (1:2000, Chemicon) overnight. The next day the sections were incubated 
for 2 h with the biotinylated goat anti-rabbit secondary antibody (1:200, Vector). The 
standard avidin-biotin reaction was performed using Vectastain® Elite ABC peroxidase 
Kit and the immunoreactivity was revealed using diaminobenzidine (DAB) and H2O2. The 
sections were mounted on gelatin/chrome alume-coated slides, air-dried overnight, 
dehydrated through graded ethanols, cleared in xylene and coverslipped.  
DAT immunohistochemistry. Striatal free-floating sections used for densitometry 
measurements (40 µm) were processed as described above for TH, with the exception that 
the primary antibody was rat anti-DAT monoclonal antibody at 1:2000 (Chemicon) and 
secondary antibody was biotinylated rabbit anti-rat antibody at 1:200 and normal rabbit 
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serum (Vector Laboratories) was used instead of normal goat serum. Striatal sections (30 
µm) used for stereological estimation of DAT-positive varicosities were incubated for 48 
h (at +4ºC) and the concentration of primary antibody was increased to 1:1000 
(Chemicon).  
4.3.3 Quantification of immunoreactivity 
Striatal densitometry measurements. Digitalized images of TH and DAT immunostained 
striatal sections were collected and optical density (OD) of the stainings was measured 
using Image-Pro-Plus TM software (Version 3.0.1., Media Cybernetics, Silver Spring, 
MD). For each animal, the OD was measured from three striatal coronal sections and the 
final reading was calculated as an average of those three values. The nonspecific 
background correction in each section was done by subtracting OD value of corpus 
callosum from the striatal OD value obtained from the same section.  
Stereological analysis of TH-positive cells and DAT-positive varicosities. From each 
animal, three TH-immunostained midbrain sections were selected, and TH-positive somas 
lateral to the medial terminal nucleus (MTN) were counted. The counts were made at 60X 
under oil, and with help of the StereoInvestigator software with optical fractionator 
according to optical dissector rules (Gundersen et al., 1988). After SNpc estimations were 
performed, the same sections were used for counting of TH-positive cells in the VTA. TH 
staining was used to define the outline of the VTA with the MTN as the lateral border. 
The number of DAT-immunoreactive (DAT-IR) punctuate structures in the striatum was 
determined using a stereology approach similar to that described previously (Parish et al., 
2001). From each animal, four DAT-immunostained striatal sections were analysed at 
100X under oil. The DAT-positive terminals were identified as round swellings in 
association with axons and used as counting units. The total number of the DAT-positive 
punctuate structures on one side for each striatum was determined by the 
StereoInvestigator program. The coefficient of error was calculated as an estimate of 
precision and values under 0.1 were accepted. The person performing counting was 
blinded as to the identity of the samples. 
4.4 Immunoblotting (Study I) 
Western blotting experiments were performed from individual dorsal striatal tissues and 
SN/VTA tissues pooled from five mice of the same genotype. Individual striata were 
homogenized in lysis buffer (5mM HEPES, pH 7.4, 320mM sucrose, 1mM EDTA, 
0.1mM PMSF and 0.1% SDS), the homogenates were centrifuged at 900 X g for 3 
minutes and the supernatants were further centrifuged at 16 000 X g for 20 minutes. 
Thereafter, the supernatant was collected and protein concentration was determined by a 
commercial protein assay BCA kit (Pierce, Rockford, IL). The samples containing equal 
amounts of protein (15µg) were loaded on and electrophoresed in a 7.5% SDS-
polyacrylamide gel and then transferred onto Protran® nitrocellulose transfer membranes 
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(Schleicher & Schuell Bioscience GmbH, Daseel, Germany). After blocking of 
nonspecific binding with 5% nonfat dry milk, the membranes were then probed with sheep 
anti-TH polyclonal antibody (at 1:1000; Chemicon) and rat anti-DAT monoclonal 
antibody (at 1:500; Chemicon). Next, membranes were treated with appropriate secondary 
antibody (1:2000) conjugated with horseradish peroxidise (HRP), and blots were 
visualized with chemiluminescent substrate (Pierce, Rockford) detected and estimated 
using GeneGnome chemiluminescent detector and its software (SynGene, Synoptics LTD, 
UK). The membranes were then stripped of antibodies and afterwards re-probed with 
mouse anti-actin antibody at 1: 10000 (Sigma) and appropriate anti-mouse HRP-
conjugated secondary antibody (1:2000, Zymed). The stripping protocol included shaking 
the membranes in 40% methanol for 30 min at room temperature, followed by submersion 
in stripping buffer containing: 2% SDS, 62.5mM Tris HCl, 100mM β-mercaptoethanol, at 
55°C for 30 min.  Five-percent nonfat milk was used for blocking. 
After the homogenization of the SN/VTA samples, normalized amounts of protein 
sample (10µg) were loaded on a 10% SDS-polyacrylamide gel, transferred onto Hybond 
ECL Nitrocellulose membrane (Amersham Biosciences) which was then probed with anti-
TH antibody and subsequently treated with horseradish peroxidase conjugated secondary 
antibody. The blots were visualized by chemiluminescent substrate (Pierce). The images 
were taken using LAS 3000 CCD Camera from Fujifilm and quantified using the AIDA 
Image Analyzer software.  
4.5 Drugs and treatments 
NSD-1015 (Study II, BioChemika, Sigma, China), alpha-methyl-paratyrosine (Study II, α-
MT, Labkemi AB, Sweden),  tetrabenazine (Study II, Tocris, Avonmouth, UK), cocaine 
(Studies I and II, University Pharmacy, Helsinki, Finland), haloperidol (Study II, Janssen 
Pharmaceutica N.V., Beerse, Belgium), MPTP (Study III, Toronto Research Chemicals) 
and d-amphetamine (University Pharmacy, Helsinki, Finland) were dissolved in saline 
(0.9% NaCl). Control animals received saline. All the injections were given i.p. in a 
volume of 10 ml/kg. Drug doses were calculated as free base.  
Five μg of 6-OHDA (Study III, Sigma, USA) was injected into the left striatum using 
stereotaxic frame and injector. The mice were pretreated with desipramine (25 mg/kg, i.p.) 
30 min before 6-OHDA. 6-OHDA·HCl was dissolved in 0.02% ascorbic acid solution and 
using a 10 μl Hamilton syringe was infused into the left striatum (total volume injected 
was 2 μl, rate of injection was 0.5 μl/min). The needle was slowly retracted 2 min from the 
cessation of injection.  
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4.6 Stereotaxic Surgery (Study II and III) 
The mice were under general isoflurane (3.5% induction, 2% maintenance) and local 
lidocaine anesthesia while using the stereotaxic device (Stoelting, Wood Dale, IL, USA) 
to implant microdialysis guide cannulae or to inject 6-OHDA into striatum. Mice were 
given buprenorphine (0.1 mg/kg s.c.) to relieve pain. Guide cannulae were aimed in the 
striatum above the point (A/P = + 0.6, L/M = +1.8 and D/V = -2.3) and 6-OHDA was 
infused into left striatum at coordinates AP + 0.7, ML +1.8, DV -2.7 relative to bregma 
and dura according to mouse brain atlas (Franklin and Paxinos, 1997). After surgery, mice 
were placed into individual test cages and allowed to recover in the cages for 5-7 days 
before the microdialysis experiment whereas 6-OHDA-treated mice were used 3 weeks 
later for neurochemical, histological and behavioral analysis. 
4.7 In vivo microdialysis (Study II) 
On the previous afternoon, a microdialysis probe (AgnTho’s, Lidingö, Sweden, 1 mm 
membrane, outer diameter 0.24 mm) was inserted into the guide cannula, and the probe 
was infused with Ringer solution at a low flow rate of 0.5 μl/min. In the morning of the 
experimental day, the flow rate was increased to 2 μl/min, and after a 2 h of stabilization 
period, the collection of actual microdialysis samples (every 20 min, 40 μl/sample) was 
started. The concentrations of DA, DOPAC and HVA were determined by HPLC with an 
electrochemical detector (Coulochem ΙΙ; ESA Inc., Chelmsford, MA, USA). Basal steady-
state extracellular monoamine concentrations were determined as mean of concentrations 
of four stable pre-drug samples collected during the first 80 minutes of sampling (variation 
< 20%). Post-drug neurotransmitter levels were converted to a percentage of this baseline 
value, which was defined as 100%. Potassium stimulation was performed by manually 
switching the perfusion medium, Ringer, to the one containing 100 mM KCl and 27.5 mM 
NaCl (remaining composition not changed). After completion of the experiments, the 
positions of the probes were verified histologically.  
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4.8 In vivo voltammetry (Study II) 
4.8.1 Preparation of animals 
The mice were anaesthetized with chloral hydrate (450 mg/kg, i.p.) and fixed to a 
stereotaxic frame. The carbon fiber working electrode was inserted through an opening in 
the skull to the caudate nucleus (A/P= +1.18 mm, L/M = +1.5 mm, H =3.4 mm vs. 
bregma) and a bipolar stimulating electrode was implanted in the medial forebrain bundle 
(A/P +2.1 mm, L/M +1.1 mm, H: 5.0–5.2 mm vs. bregma) according to mouse brain atlas 
(Paxinos and Franklin 2000). The exact placement of the stimulating electrode in the 
dorsoventral coordinate was adjusted for maximal dopamine release. A small leak-free 
Ag/AgCl reference electrode (AH 69-0023, Harvard Apparatus, Holliston, MA, USA) in a 
saline bridge was placed on the skull. A stainless steel screw was fixed onto the skull as 
the auxiliary electrode. 
4.8.2 Electrochemical technique 
Stimulated release of dopamine was measured using constant potential amperometry 
(CPA). A single Nafion-coated carbon fiber, 30 µm in diameter (WPI, Sarasota, FL, USA) 
was protruded in pulled capillary glass and insulated with epoxy glue. The exposed tip of 
the fiber was 300 µm. A custom-built three-electrode potentiostat held the working 
electrode at 0.4 V against an Ag/AgCl reference electrode. The current at the working 
electrode was converted to voltage at a headstage converter located near the working 
electrode. The data were digitized at 10 KHz and recorded with a personal computer for 
further off-line analysis. The electrochemical signals in response to stimulations were 
stabilized in about 90 min after implantation of the working electrodes. After the 
experiments, the working electrodes were rinsed with deionized water and calibrated for 
dopamine in phosphate-buffered saline (pH = 7.4).  
4.8.3 Electrical stimulation and experimental protocol 
A battery-operated constant current unit (A365, WPI) run by a personal computer was 
used for the stimulation. Constant current pulses (1 ms in duration) of 180–200 µA were 
delivered to the stimulation electrode at 10–60 Hz in 2 s bursts. The intervals between the 
bursts were 1–6 min. Longer intervals corresponded with higher stimulation frequencies. 
Another stimulation protocol was used to obtain peaks of DA overflow of different 
amplitudes, from which peaks of similar amplitudes can be directly compared. We used 50 
Hz stimulations applied in the bursts of 0.2, 0.4, 0.8, and 1.6 s lengths at 1–4 min 
intervals. 
The right slope of the dopamine overflow curve reflects dynamics of dopamine 
elimination from the extracellular space. This curve can be approximated with a good fit 
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by a standard exponential function f(t) = Ae-t/τ + C. Curve fitting was made with Clampfit 
v.8 (Axon Instruments/Molecular Devices Corporation, Sunnyvale, CA, USA) with peaks 
of similar amplitudes. We analysed and depicted dopamine decay from the extracellular 
space using parameter tau (τ) which is time constant of dopamine decay curve. The effect 
of cocaine was analyzed 25–45 min after the administration at different stimulation 
frequencies (10–60 Hz, 2 s burst length) and lengths (0.2–1.6 s, at 50 Hz). 
4.9 Behavioral testing methods (Study I and III) 
Locomotor activity. A detailed description can be found in the study I. In brief, the mice 
were put into transparent plastic cages, infrared photobeam interruptions caused by mice 
movement were registered by activity monitors and distance traveled in a period of time 
was measured (MED Associates, Open field activity monitor, ST. Albans, GA). Except 
when spontaneous locmotor activity was assessed, the mice were habituated to the test 
cages for 5 - 10 minutes.  
Turning behavior. Amphetamine-induced turning behavior was measured using Roto-
RatTM test system (Med Accociates Inc., Georgia, VT, USA). On the morning of 
experiment the mice were placed into individual bowls and attached via collars (put on the 
previous evening) to the leashes that extend from the sensitive optical encoders which 
report movements in either direction. The animals were left to habituate to the bowls for 
15min before single d-amphetamine injection (University Pharmacy, Helsinki, Finland; 3 
mg/kg i.p.) and the number of full 360◦ ipsilateral (body turns toward the side of lesion) 
and contralateral turns (body turns away from the side of lesion) was recorded for a period 
of 90 min. The data were expressed as net ipsilateral turns.  
4.10 Statistical analyses  
Data are presented as mean ± S.E.M and a level of p < 0.05 was taken as a statistically 
significant effect. Data obtained from monoamine tissue measurements were analyzed 
with one-way or two-way ANOVA, followed by Tukey/Kramer post hoc comparisons 
(Study I and II) or Student-Newman-Keuls post hoc test (Study III). One-way ANOVA 
and Tukey/Kramer  post hoc test were used to analyze statistically significant differences 
in steady-state extracellular concentrations of DA, DOPAC and HVA between genotypes 
(Study II). One-way ANOVA for repeated measures was used to analyze the drug effects 
on output of extracellular levels of DA and DOPAC in MEN2B mice and their wild-type 
littermates (Study I). Locomotor activity data were analyzed with two-way ANOVA for 
repeated measures and Tukey/Kramer post hoc test (Study I). In voltammetry experiments 
(Study II) the effects of cocaine on peak dopamine overflow after stimulations at 
increasing frequencies were statistically analyzed with multivariate analysis of variance 
for repeated measures (MANOVA). Also, MANOVA was used to compare time constants 
of uptake in two genotypes and after cocaine, and a t-test was used for comparison of 
 
 
 
 
33
individual pairs. The numbers of TH-positive cells and those of DAT-positive varicosities 
in the Wt and homozygous M/M mice were compared by unpaired Student’s t-test (Study 
I). The effects of 6-OHDA or MPTP on TH-positive cell numbers in the SN were 
analyzed with two-way ANOVA followed by Student-Newman-Keuls post hoc test (Study 
III). 
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5. RESULTS 
5.1 Monoamine concentrations in different brain areas of the 
MEN2B mice (Study I) 
The analysis of monoamine levels in the different brain tissues (striatum, cortex, 
hypothalamus, hippocampus and lower brain stem) revealed that in the MEN2B mice, 
dopamine concentrations were increased in the target areas of the dopaminergic neuronal 
pathways (Table 5.1 and Figure 5.1).  
 
 
Table 5.1. Post mortem, cerebral tissue concentrations of DA, NA and 5-HT (ng/g 
of wet tissue) in the M/+ and M/M mice as compared with the Wt mice.  
  DA NA 5-HT 
Striatum   
 M/+ ↑↑** nd ↔ 
 M/M ↑↑↑** ## nd ↔ 
Cortex   
 M/+ ↑↑** ↔ ↔ 
 M/M ↑↑** ↔ ↔ 
Hypothalamus   
 M/+ ↔ ↔ ↔ 
 M/M ↑* ↔ ↔ 
Hippocampus   
 M/+ nd ↔ ↔ 
 M/M nd ↔ ↔ 
Lower brain stem   
 M/+ ↔ ↔ ↔ 
 M/M ↑ ↑* ↔ 
Arrows indicate the increase in the concentration of a monoamine in the MEN2B mice as 
compared with the Wt: ↑ indicates 20-35% increase, ↑↑ 40-80% and ↑↑↑ more than 80% increase. 
↔ indicates no change; nd indicates that a neurotransmitter was not detected. One-way ANOVA 
and Tukey/Kramer post hoc test were used for statistical analysis: **p < 0.01 vs. Wt mice; #p < 
0.05, vs. M/+ mice 
 
 
In the whole striatum, DA concentrations were increased in the heterozygous M/+ mice by 
47% and in the homozygous M/M mice by 100%, as compared with the Wt mice. Cortical 
DA was similarly increased in both M/+ and M/M mice (by about 70%), whereas in the 
hypothalamus, DA was significantly elevated (by about 30%) only in the M/M mice 
(Table 5.1). 
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As shown in Figure 5.1, in the dorsal striatum the tissue content of DA was increased by 
54% in the M/+ and by 94% in the M/M mice, as compared with Wt mice. In the ventral 
striatum, however, DA levels were comparable between M/+ and M/M mice, and by about 
60% higher in both than in the Wt mice (Figure 5.1). In conjunction with DA, 
concentrations of DOPAC and HVA in the MEN2B mice were augmented in the 
aforementioned brain tissues in comparison to Wt mice (Figure 5.1). In the dorsal striatum 
of M/+ mice, DOPAC was up by 102% and HVA by 72%, while in the M/M mice, 
DOPAC was increased by 185% and HVA by 137%. Thus, as is the case with DA, 
concentrations of DOPAC and HVA in the dorsal striatum were significantly higher in the 
M/M than in the M/+ mice. In the ventral striatum, DOPAC and HVA were similarly 
increased in the M/+ and M/M mice (DOPAC: by 120-130% and HVA: by 80%; Figure 
5.1). 
 
Figure 5.1. Concentrations (nanograms per gram) of dopamine, DOPAC and HVA in the dorsal 
(A) and ventral (B) striatum of the M/+ and M/M mice were elevated as compared with their Wt 
littermates. Furthermore, in the dorsal striatum, dopamine and its metabolites were increased in 
the gene dosage-dependent manner whereas in the ventral striatum, the maximal effect could 
already be observed in the heterozygous mice. Statistical results were obtained with one-way 
ANOVA and Tukey-Kramer post-hoc analysis. *p < 0.05 vs. Wt mice, *p < 0.01 vs. Wt mice, #p < 
0.05 vs. M/+ mice, ##p < 0.01 vs. M/M mice. 
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In contrast to DA, concentrations of serotonin were not changed in any of the analyzed 
tissues in both heterozygous M/+ and homozygous M/M mice. Likewise, the 
concentrations of noradrenaline did not differ among the mice of all three genotypes, 
except in the lower brain stem where NA was slightly increased (by 27%) in the 
homozygous M/M mice (Table 5.1). 
5.2 TH and DAT expression in the nigrostriatal DAergic system of 
MEN2B mice (Study I) 
Next, we examined whether other dopaminergic markers, such as TH and DAT, are 
altered in the MEN2B mice. Indeed, optical densities of the TH-immunostained striatal 
sections in the M/+ and M/M mice were found to be 55% and 75% larger than in the Wt 
mice, respectively (Table 5.2). Thus, we again found a dose-dependent effect of the gene 
mutation on DAergic system in the M/+ and M/M mice. Intensity of DAT-
immunostaining in the striatum was increased by about 50% in both M/+ and M/M mice 
as compared with Wt mice (Table 5.2). Western blotting analysis confirmed that striatal 
TH and DAT levels are indeed increased in M/+ and M/M mice (Study I, Figure 3A and 
3B). In the SN/VTA region, levels of TH protein were assessed by Western blotting 
analysis and found to be elevated by  60% and 180% in the M/+ and M/M mice, 
respectively, as compared with Wt mice (Study I, Figure 3C).  
 
Table 5.2. Striatal optical density of TH- and DAT-immunostained striatal 
sections in the M/+ and M/M mice as compared with Wt mice 
 TH OD DAT OD  
M/+ ↑* ↑**  
M/M ↑↑** ↑**  
↑ indicates 50-60% increase and ↑↑ indicates more than 70% increase in the M/+ and M/M mice as 
compared with the Wt mice. One-way ANOVA and Tukey/Kramer post hoc test were used for 
statistical analysis: *p < 0.05 vs. Wt mice, **p < 0.01 vs. Wt mice.  
 
 
When quantitative real-time PCR was used, about 2.5-fold increase in the levels of TH 
mRNA in the SN/VTA of the homozygous M/M mice was observed. Also, levels of DAT 
mRNA in the SN/VTA were raised in the M/M mice (by about 2.7 fold), but the 
difference did not reach statistical significance. The levels of other genes studied, such as 
GDNF, GFRα1 and NCAM in SN/VTA and GDNF in striatum, were not changed in the 
M/M mice. 
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5.3 The numbers of midbrain TH-positive cells and striatal DAT-
positive varicosities in the MEN2B mice (Study I) 
Stereological analysis of TH-stained sections revealed a 26% increase in the number of 
TH-positive neurons in the SNpc in the homozygous M/M mice compared with their Wt 
littermates (Table 5.3).  No increase in the number of nigral TH-positive cells was found 
in the heterozygous M/+ mice. In the VTA, the number of TH-positive cells did not differ 
among Wt, M/+ and M/M mice (Table 5.3).  
The number of DAT-positive punctate structures in the striatum of the MEN2B mice 
was counted in order to assess possible sprouting of dopaminergic fibers in the striatum 
under influence of constitutive Ret activity. A significant increase in the number of DAT-
positive varicosities in the striatum was found only in the homozygous M/M (by about 
23%) and not in heterozygous M/+ mice, as compared with their Wt littermates (Table 
5.3).  
 
 
Table 5.3.  Numbers of TH-positive cells in the SNpc and VTA and of DAT-
positive varicosities in the striatum of M/+ and M/M mice as compared with Wt mice.  
  TH-positive cells DAT-positive varicosities 
 SNpc VTA Striatum 
 M/+ ↔ ↔ ↔ 
 M/M ↑* ↔ ↑* 
↑ indicates significant increase of about 20-25% and ↔ indicates no change in comparison with Wt 
mice. *p < 0.05 vs. Wt mice as revealed by Student’s t-test 
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5.4 Brain dopamine concentration at different developmental 
stages in the MEN2B mice (unpublished) 
The next objective was to assess the role of the Ret signaling during the development of 
the DAergic system. Therefore, we estimated brain DA levels in the MEN2B mice at 
different developmental stages (Table 5.4). At the embryonic day 18 (E18), there were no 
differences in the brain DA concentration between the genotypes. Also, at the postnatal 
day 7 (P7), no alterations in the brain DA levels in the MEN2B mice were observed, as 
compared to the Wt mice. However, at postnatal day 16 (P16), brain DA levels were 
significantly increased by about 55% in the homozygous M/M mice as compared with Wt 
mice. Also, at P16, brain DA in the heterozygous M/+ mice was elevated by about 22%, 
though the difference did not reach statistical significance. 
 
 
Table 5.4. Brain DA concentration at embryonic day 18 (E18), postnatal day 7 
(P7) and postnatal day 16 (P16) in the M/+ and M/M mice, as compared with the Wt 
mice 
 E 18 P7 P16 
M/+ ↔ ↔ ↑ 
M/M ↔ ↔ ↑↑** ## 
↔ indicates no change, ↑ indicates 20-25% increase and ↑↑ indicates 50-55% increase of brain DA 
concentrations in the M/+ and M/M mice as compared with the Wt mice. One-way ANOVA and 
Tukey/Kramer post hoc test were used for statistical analysis:  **p < 0.01 vs. Wt mice, ## p < 0.01 
vs. M/+ mice. n = 6-14/ group. 
 
5.5 Assessment of locomotor activity in the MEN2B mice (Study 
I) 
Spontaneous locomotor activity in nonhabituated Wt, M/+ and M/M mice declined during 
the 60 min in a similar fashion. Nevertheless, both M/+ and M/M mice showed reduced 
locomotor activity as compared with the Wt mice, while no differences between M/+ and 
M/M mice were found (Study I, Figure 6). However, after the mice were habituated and 
locomotor activity was recorded over 24 h, no differences in the distances traveled or time 
points of activity peaks between the mice of the three genotypes were found (Study I, 
Figure 6).  
Next, the mice were given cocaine (5, 10 or 20 mg/kg) or saline, and locomotor 
activities were recorded for 30 min. Cocaine significantly and dose-dependently increased 
locomotor activity in mice of all three genotypes, but its effects differed between the Wt 
and MEN2B mice. The effect of 5 mg/kg of cocaine was similar in all genotypes but doses 
of 10 and 20 mg/kg of cocaine increased locomotor activity significantly more in 
heterozygous M/+ and homozygous M/M mice than in Wt mice. Furthermore, the 
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homozygous mice treated with 20 mg/kg cocaine traveled a significantly longer distance 
than their correspondingly treated wild-type littermates. Locomotor activities of saline-
treated MEN2B mice and their wild-type littermates did not differ significantly (Figure 
5.6).  
 
 
 
Figure 5.6. The effects of acute cocaine administration on the locomotor activities of heterozygous 
M/+ mice, homozygous M/M mice and their wild-type littermates (Wt). Saline or cocaine (5 mg/kg, 
10 mg/kg or 20 mg/kg) were given i.p. immediately before starting the recording. Columns give 
means ± SEM of total distances traveled during 30 min. *p < 0.05, **p < 0.01 as compared to 
corresponding saline treated mice; ##p < 0.01 as compared to cocaine 20 mg/kg treated Wt mice 
(Tukey/Kramer post hoc test) 
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5.6 Synthesis and storage of DA in the MEN2B mice (Study II) 
Based on the findings that the levels of both dopamine and TH were augmented in the 
striatum of M/+ and M/M mice, the next objective was to examine if synthesis and storage 
of dopamine were increased in the DA neuron terminals in the striatum in the MEN2B 
mice.  
A good indicator of TH activity and DA synthesis is the degree of L-DOPA 
accumulation after blocking its conversion to DA. Following the inhibition of DOPA 
decarboxylation by NSD-1015 (150 mg/kg), striatal L-DOPA levels were increased by 
41% in the M/+ and by 68% in the M/M mice as compared with their Wt littermates 
(Figure 5.7) showing that TH activity and DA synthesis are indeed enhanced in MEN2B 
mice.  
 
 
 
Figure 5.7. Increased NSD-1015-induced L-DOPA accumulation in the M/+ and M/M mice as 
compared with Wt mice. The columns give the concentrations of L-DOPA (means ± SEM). 
Statistical results were obtained with one-way ANOVA and Tukey/Kramer post hoc test. **p < 
0.01; n = 7-15/genotype. 
 
 
The α-methyl-para-tyrosine (αMT) is an inhibitor of TH and causes exhaustion of the 
newly synthesized, so-called releasable pool of intracellular dopamine. Tetrabenazine, a 
VMAT2 blocker, depletes the storage pool of intracellular dopamine, thereby causing 
subsequent accumulation of DOPAC. The elevated response of M/+ and M/M mice 
(striatal DA depletion was 33% and 40%, respectively) to αMT (250 mg/kg) compared to 
that of the Wt mice (DA depletion 27%) suggests that releasable pool of dopamine in M/+ 
and M/M mice is augmented in comparison to the Wt mice (Figure 5.8A). Also, it 
substantiates the finding that the activity of TH is increased in these mice.  Likewise, after 
tetrabenazine (5 mg/kg), DA depletion was enhanced in M/+ and M/M mice (75% and 
81%, respectively) as compared with Wt mice (69%, Figure 5.8B). Accordingly, 
tetrabenazine-induced accumulation of striatal DOPAC was larger in the M/+ and M/M 
mice (341% and 373%, respectively) than in the Wt mice (279%) (Study II, Figure 3.B). 
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Thus, the augmented tetrabenazine response indicates that storage pool of dopamine is 
larger in MEN2B mice that in the Wt mice.  
 
 
 
 
 
 
Figure 5.8.  The effects of alpha-methyl-paratyrosine (αMT, 250 mg/kg, i.p.) and tetrabenazine 
(TBN, 5 mg/kg, i.p.) on depletion of dopamine (DA) in the M/+ and M/M mice as compared with 
Wt mice. The columns give the concentrations of DA (means ± SEM).The αMT-induced DA 
depletion was larger in the M/+ and M/M mice (genotype X treatment interaction p = 0.0391, two-
way ANOVA). Also, TBN depleted DA more in the M/+ and M/M mice (genotype X treatment 
interaction p = 0.0001, two-way ANOVA). 
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5.7 Effects of cocaine, haloperidol and high K+ stimulus on 
extracellular concentrations of dopamine, DOPAC and HVA in 
striatal dialysates in the MEN2B mice (Study II) 
 
Basal extracellular DA concentrations in the dorsal striatum were similar among the three 
genotypes, as revealed by microdialysis (Table 5.5). However, concentrations of 
extracellular DOPAC were significantly higher in the dorsal striatum in the M/+ (by 58%) 
and M/M (by 71%) mice as compared with the Wt mice (Table 5.5). Basal levels of HVA 
in both M/+ and M/M mice were elevated by about 30%, but not significantly (Table 5.5).  
 
Table 5.5. The basal, steady-state extracellular concentrations of DA, DOPAC 
and HVA in the striatal dialysates in the M/+ and M/M mice as compared with Wt 
mice 
 DA DOPAC HVA 
M/+ ↔ ↑↑** ↑ 
M/ M ↔ ↑↑** ↑ 
↔ indicates no change, ↑ indicates 30-35% increase and ↑↑ indicate 50-80% increase in the 
concentration of DA or its metabolites in the M/+ and M/M mice as compared with the Wt mice. 
One-way ANOVA and Tukey/Kramer post hoc test were used for statistical analysis: **p < 0.01 
vs. Wt mice.  
 
Effects of dopamine uptake blocker, cocaine (10 and 20 mg/kg, i.p.), D2-type receptor 
blocker, haloperidol (0.5 mg/kg, i.p.) and high K+ (100 mM KCl) stimulus on striatal 
dopamine release were studied by microdialysis. Unexpectedly, there was no difference 
among the genotypes in the increase of extracellular dopamine concentrations in the 
response to either dose of cocaine (Study II, Figures 5.A and 5.B). High K+ stimulation via 
microdialysis probe increased the output of DA similarly in all three genotypes (Study II, 
Figure 5.B). Also, no difference among genotypes was found in the effect of haloperidol 
on extracellular DA concentration in the dorsal striatum (Study II, Figure 6.A). 
Nevertheless, haloperidol increased extracellular DOPAC concentration significantly more 
in M/M mice than in the M/+ and Wt mice (Study II, Figure 6.B).  
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5.8 In vivo voltammetry assessment of uptake and release of 
dopamine in the dorsal striatum of the MEN2B mice (Study II) 
As revealed by in vivo voltammetry, the M/M mice showed a much larger increase in 
stimulated peak dopamine overflow in comparison with the Wt mice (Study II, Figures 
7.A and 7.B). Also, dopamine decay from extracellular space was three times faster in the 
M/M mice than in the Wt mice (Study II, Figure 8.B) and the effect of cocaine on 
dopamine elimination was significantly larger in the M/M mice (Study II, Figure 8.C). 
Taken together, the data obtained by in vivo voltammetry reveal that both release and 
uptake of dopamine are increased in the MEN2B mice.  
5.9 Effects of systemic MPTP on the dopaminergic system of 
MEN2B mice (Study III)  
Two weeks after MPTP treatment, there was a similar decline in dopamine concentrations 
(by about 45%) in the dorsal striatum in the Wt, M/+ and M/M mice as compared with 
their saline-treated controls (Table 5.6). Likewise, MPTP lowered striatal TH-
immunostaining similarly in all three genotypes (by about 15-20 %).  However, MPTP did 
not induce the loss of TH-positive cells in the substantia nigra pars compacta in any of the 
genotypes (Study III, Figure 3). Unlike in the Wt mice, we found no compensatory 
increase in striatal DOPAC/DA ratio in the MPTP-treated MEN2B mice as compared with 
their saline-treated controls (Table 5.6). No difference in the HVA/DA ratio among the 
genotypes was found.  
 
Table 5.6. Summary of the effects of MPTP treatment on DA depletion, TH-
immunostaining and DOPAC/DA ratio in the striatum of M/+ and M/M mice as 
compared with Wt mice 
        DA depletion TH-immunostaining DOPAC/DA ratio 
↔ ↔ ↓* 
↔ ↔ ↓* 
↔ indicates that the response to MPTP was similar to the Wt mice, ↓ indicates 35-50% 
lower response of M/+ and M/M mice as compared with the Wt mice. *p < 0.05 vs. Wt mice 
(one-way ANOVA and Student-Newman-Keuls post hoc test) 
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5.10 Effects of unilateral, striatal 6-OHDA on the dopaminergic 
system of MEN2B mice (Study III) 
There was marked decrease in the striatal dopamine levels on the lesioned side of both Wt 
and M/M mice 3 weeks following unilateral, striatal 6-OHDA lesion. The 6-OHDA-
induced DA depletion was substantial in mice of both genotypes. However, the degree of 
DA depletion was significantly smaller in the M/M mice (by about 73%) than in the Wt 
mice (by about 84%, Figure 5.9A). Morphometric analysis of TH-positive cells revealed 
that the M/M mice were much less affected by 6-OHDA than the Wt mice, as a significant 
loss of TH-positive cells in the substantia nigra pars compacta was found in the Wt mice 
(36%) while only a minor one was observed in the MM mice (9%, Figure 5.9B). 
 
Figure 5.9. The effects of intrastriatal, unilateral 6-OHDA lesion on DA levels in the striatum (A) 
and TH-positive cell number in the substantia nigra pars compacta (B) in M/M and Wt mice.  The 
6-OHDA-induced DA depletion in the striatum was less pronounced in the M/M than in the Wt 
mice. A significant decrease in TH-positive cells was found only in the Wt mice, whereas M/M 
mice were only slightly affected. 
In the M/M mice, the striatal DOPAC/DA ratio in the lesioned side was not augmented 
whereas in the control Wt mice the DOPAC/DA ratio in the lesioned side was increased 3-
fold as compared with the intact side. Also, in the lesioned striatum of the Wt mice there 
was profound elevation of HVA/DA ratio (310%) whereas there was only a modest 
increase (137%) in the M/M mice (Study III, Figure 5). The number of amphetamine-
induced turnings was increased in 6-OHDA-treated MEN2B mice by about 49% as 
compared with their 6-OHDA-lesioned Wt littermates (Study III, Figure 7).  
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6. DISCUSSION 
6.1 The effects of constitutive Ret activity on brain DA 
concentrations, production and uptake of DA in the MEN2B mice 
We found that tissue concentrations of DA and its metabolites in the target areas of brain 
dopaminergic systems were profoundly elevated in mice expressing a constitutively active 
Ret receptor (Study I). This is consistent with reports that exogenously administered 
GDNF increases DA levels and DA turnover in the striatum and SN of rodents (Hudson et 
al., 1995; Martin et al., 1996b; Lapchak et al., 1997b; Gash et al., 2005). Also, the levels 
of TH mRNA in SN/VTA and TH protein in the striatum and SN/VTA were increased in 
the MEN2B mice (Study I). This is in line with the outcome from a study showing that 
administration of GDNF promotes the transcription of the TH gene and the stability of TH 
mRNA (Xiao et al., 2002). In addition, GDNF treatment has been found to increase TH 
phosphorylation, enhancing  its activity  and  increasing DA synthesis (Kobori et al., 2004; 
Salvatore et al., 2004). In contrast, after prolonged GDNF treatment of adult rats, no 
changes in DA concentrations were observed and mRNA and protein levels of TH were 
found to be decreased (Lu and Hagg, 1997; Rosenblad et al., 2003; Georgievska et al., 
2004). This is thought to be a compensatory response of the already mature DA system to 
the initial stimulatory effects of exogenous GDNF on TH. In the MEN2B mice, on the 
other hand, Ret signaling is permanently activated from early development, when it is 
actively shaping the development of the DA system.  
Increased TH levels suggested that elevated DA concentrations in the MEN2B mice 
are a consequence of increased DA production. We verified this assumption by blocking 
DOPA decarboxylase and inhibiting the conversion of DOPA to DA. The accumulation of 
DOPA after NSD-1015 treatment was found to be higher in the MEN2B mice than in the 
controls, and thus provided direct proof that TH activity and production of DA are indeed 
enhanced in the MEN2B mice (Study II). 
We also found that the levels of DAT protein in the striatum were increased in the 
MEN2B mice (Study I). In accordance with the upregulation of DAT in the striatum, 
MEN2B mice were more sensitive to the behavioral effects of cocaine, a blocker of DAT. 
It has been shown that GDNF can increase dopamine uptake (Lin et al., 1993) and that Ret 
has an inducing effect on the expression of the DAT gene (Li et al., 2006; Li et al., 2009). 
These findings suggested that constitutive Ret activity in the MEN2B mice might have 
caused elevation of DAT levels in the nigrostriatal DAergic neurons in the first place. 
However, since the other brain DA systems that express much less or very little DAT, 
such as mesolimbic, mesocortical and tuberoinfundibular systems, have increased tissue 
DA levels and are apparently also affected by the Ret-MEN2B mutation, this is a less 
likely explanation. Thus, even though a direct effect of Ret-MEN2B mutation on DAT 
cannot be ruled out, it is more likely that constitutive Ret activity primarily affects TH and 
synthesis of dopamine and that increased DAT levels in the striatum in the MEN2B mice 
are probably a compensatory response to the increased DA levels.  
 
 
 
 
46 
6.2 The effects of constitutive Ret activity on development and 
maintenance of the nigrostriatal DA system in the MEN2B mice 
We found that adult homozygous MEN2B mice had a higher number of TH-positive cells 
in the SNpc than the Wt mice, while no difference was found in the VTA. Previous studies 
on GDNF, GFRα1 and Ret knock-out mice suggested that GDNF-Ret signaling is not 
important for prenatal, embryonic development of nigral DA neurons (Marcos and 
Pachnis, 1996; Moore et al., 1996; Pichel et al., 1996; Sanchez et al., 1996; Enomoto et 
al., 1998). Also, our finding that MEN2B mice had normal brain DA levels at embryonic 
day 18 suggested that increased Ret signaling did not affect prenatal development of DA 
system. Thus, the increase in the number of SNpc TH-positive cells in the adult 
homozygous M/M mice is likely to arise during the postnatal development of the 
nigrostriatal DA system. GDNF has been shown to increase survival of postnatal DAergic 
neurons by suppressing apoptotic cell death (Oo et al., 2003), and overexpression of 
GDNF in the striatum of a transgenic mouse model resulted in an increased number of DA 
neurons in the SNpc surviving the first phase of natural cell death, although this increase 
in DA neurons is only maintained during adulthood in the VTA but not in the SN 
(Kholodilov et al., 2004). Thus, constitutive Ret activity in the MEN2B mice may have 
suppressed the physiological postnatal cell death and resulted in the increased number of 
DA neurons in adulthood. However, the normal levels of brain DA found in the MEN2B 
mice at postnatal day 7 suggest that increased Ret activity does not result in increased 
survival of DA neurons during the first phase of ontogenic cell death. Additionally, these 
data suggest a role for an alternative GDNF signaling receptor in the regulation of this 
early phase.  
As majority of DA neurons appear during postnatal development, another possibility is 
that constitutively active Ret stimulates developing neurons to acquire a dopaminergic 
phenotype. Indeed, our data on brain DA levels at the different developmental stages 
revealed that constitutive Ret activity starts to have an effect on DA system of the MEN2B 
mice somewhere between postnatal days 7 and 16.   
Deletion of GDNF in 2-month-old mice revealed a critical role for GDNF in 
maintaining adult DA neurons (Pascual et al., 2008). Thus, under the influence of 
constitutive Ret signaling, DA neurons display increased expression of DAergic markers 
such as TH and DAT and are stimulated to produce and accommodate more DA. 
Furthermore, because of increased neurotrophic support delivered by continuously active 
Ret, the DA neurons of the MEN2B mice are better preserved, which might have resulted 
in their increased number in adulthood. Taken together, our data suggest that GDNF 
supports DA neurons and maintains DAergic phenotype during postnatal life, perhaps via 
Ret signaling.  
Interestingly, data obtained from conditional Ret knockout mice (Jain et al., 2006; 
Kramer et al., 2007) that expressed no Ret in the midbrain DA neurons starting from mid 
embryonic development suggested that Ret is not important for the establishment, 
development and maturation of the nigrostriatal DA system. Only after reaching one year 
of age did conditional Ret knockout mice exhibit progressive loss of midbrain DA 
neurons, degeneration of DA terminals and finally glial activation in the striatum (Kramer 
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et al., 2007).  It is possible that deletion of Ret from DA neurons lead to the activation of 
compensatory mechanisms that resulted in the normal development and functioning of DA 
system. Thus, by using MEN2B mice we are able to avoid compensatory changes that 
mask the importance of Ret signaling for brain DAergic system. 
6.3 Lack of the effects of constitutive Ret activity on DA fiber 
sprouting in the MEN2B mice 
It has been shown that GDNF can induce DA fiber sprouting after injury (Åkerud et al., 
1999; Kordower et al., 2000; Love et al., 2005) and Ret signaling is required for 
resprouting after MPTP treatment (Kowsky et al., 2007). Thus, we examined the 
possibility that increases in the levels of DA, TH and DAT in the striatum of MEN2B 
mice could be due to increased sprouting of DAergic fibers under the influence of 
constitutive Ret activity. We found about a 20% increase in the number of DAT-IR 
varicosities in the striatum of homozygous MEN2B mice (Study I). This increase in the 
number of DAT-IR punctate structures correlated with a 26% increase in the number of 
TH-positive cells in the SN. Therefore we concluded that no additional sprouting of DA 
neurons occurred because of constitutively active Ret in MEN2B mice. Also, in line with 
our finding, overexpression of GDNF in the target areas of mesencephalic DA neurons 
lead to the similar increases in the number of VTA DAergic neurons and their innervation 
of cortex (Kholodilov et al., 2004). Thus, increased Ret signaling is not sufficient to 
increase fiber sprouting under physiological conditions, but rather it supports repair of the 
DA fiber innervation in the striatum after injury (Kowsky et al., 2007).  
6.4 The effects of constitutive Ret activity on noradrenergic 
system in the MEN2B mice 
It has been found that the NA neuronal population expresses Ret receptor (Trupp et al., 
1997; Glazner et al., 1998). Also, it has been shown that GDNF prevents 6-
hydroxydopamine induced degeneration of NA neurons, promotes their phenotype in vivo 
(Arenas et al., 1995) and is important for the development of NA neurons in the LC-HIP 
pathway (Quintero 2004). In contrast to findings from conventional GDNF knockout 
mice, which suggest that GDNF does not promote the development and survival of LC 
NA neurons (Moore et al., 1996; Sanchez et al., 1996), a study using a conditional GDNF 
knockouts demonstrated that GDNF is essential for survival of adult LC NA neurons 
(Pascual et al., 2008). The concentration of NA was unaffected in target areas of LC 
noradrenergic neurons in the MEN2B mice (Study I), suggesting that constitutive Ret 
activity did not affect NA neurons.  Also, adult conditional Ret knockout mice did not 
show loss of NA neurons in the LC (Kramer et al., 2007). Taken together, this may 
indicate that GDNF signaling via Ret is not involved in the development and maintenance 
of LC NA neurons, but that signaling receptors other than Ret may be important in the 
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regulation of the NAergic system. Nevertheless, it has been shown that A5 NA neurons in 
the lower brain stem are GDNF-responsive (Huang et al., 2005). This may explain 
moderately increased NA concentrations we found in the lower brain stem of homozygous 
MEN2B mice (Study I).  
6.5 Striatal DAergic neurotransmission in the MEN2B mice 
Numerous studies have proven that DAergic neurotransmission is under tight homeostatic 
control. Thus, the increases in the synthesis and tissue concentration of DA observed in 
the MEN2B mice imply that there are complex compensatory alterations occurring in 
DAergic transmission. Therefore, we investigated different aspects of DAergic 
transmission such as storage, release and re-uptake of DA in the nigrostriatal system of 
these mice.  
Firstly, we found increased responses of the MEN2B mice to the effects of α-MT and 
tetrabenazine, suggesting that releasable (αMT–sensitive) and storage pools of DA 
(reserpine/tetrabenazine-sensitive) are larger in these mice. In other words, the data 
suggest that DAergic neurons in the MEN2B mice are very capable of accommodating 
large amounts of DA.  
It has been shown that augmented DA synthesis and VMAT2 activity lead to increased 
DA release (Pothos, 2002). Therefore, we expected to find increased release of DA and 
higher extracellular DA concentrations in the MEN2B mice. However, in our 
microdialysis studies, no difference in basal concentration of extracellular DA was found, 
nor was there any difference in the K+-evoked DA output between the genotypes (Study 
II). DAT provides one of the most efficient and important mechanisms to rapidly clear the 
released DA from extracellular space. Thus, increased striatal DAT levels in parallel with 
the stronger behavioral response to cocaine in the MEN2B mice compared to the Wt mice 
(Study I), suggested that increased DA uptake fully compensates for augmented DA 
release in the striatum. However, we were unable to confirm this since cocaine, a DAT 
blocker, similarly increased extracellular DA in striatal microdialysates in all genotypes. 
In addition to DAT, D2-type dopamine autoreceptors control extracellular DA levels 
through the regulation of DA synthesis, DA release and neuronal activity of DAergic 
neurons. However, no differences in the effect of D2-receptor antagonist, haloperidol, on 
the DA concentrations in striatal microdialysates were found, indicating that the function 
of D2 autoreceptors controlling the release/neuronal activity of DA is not altered in the 
MEN2B mice. 
Because microdialysis is rather ineffective (or too slow) to identify the compensatory 
mechanism that regulates DAergic neurotransmission in MEN2B mice, we employed in 
vivo voltammetry, a method with high temporal resolution used for investigation of rapid 
events associated with neurotransmission.  Indeed, data obtained with in vivo voltammetry 
(increased DA peak overflow and faster clearance of DA from extracellular space in the 
MEN2B mice) directly shows that both the release of DA and uptake of DA are increased 
in these animals (Study II). Taken together, our data indicate that enhanced synthesis of 
DA in the MEN2B mice is accompanied by larger storage of DA resulting in elevated 
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tissue DA concentrations in presynaptic DAergic terminals in striatum. These changes 
further resulted in greater release of DA, which is counteracted by higher DAT activity. 
6.6 Locomotor activity of the MEN2B mice 
Enhanced DAergic transmission is linked to motor hyperactivity. However, over a 24-h 
period, the MEN2B mice traveled distances similar to those of the Wt mice (Study I). We 
speculate that 24-h locomotion of MEN2B mice is not altered due to the substantial 
compensation in their DAergic transmission. Also, this finding suggested that there are no 
major deficits in the sensorimotor system of the MEN2B mice. The finding that MEN2B 
mice were more sensitive and responded more strongly to the stimulatory effects of 
cocaine than the Wt mice is in line with increased levels and activity of DAT. Thus, since 
DAergic ending in the striatum in the MEN2B mice are loaded with DA, blocking DAT 
should lead to greater DA output and subsequently increased hyperlocomotion. The cause 
of reduced exploratory activity of MEN2B mice remains unclear.  
6.7 The effects of toxins on DAergic system of MEN2B mice - role 
of the constitutive Ret activity in the neuroprotection 
Numerous studies in vitro and in animal models of PD have shown that GDNF is a very 
potent neurotrophic factor that protects DA neurons against neurotoxic injury. However, it 
is not known which of the neuroprotective properties of GDNF can be ascribed to 
signaling via Ret. Therefore, the next objective of the present work was to try to clarify the 
role of Ret in neuroprotection of the nigrostriatal DAergic system. The effects of the 
neurotoxins, 6-OHDA and MPTP, on the DAergic system of MEN2B mice were studied 
in order to examine whether continuous Ret signaling could protect DA neurons.  
The 6-OHDA treatment only slightly affected the MEN2B mice, whereas it caused 
significant loss of TH-positive cell bodies in the substantia nigra pars compacta in the Wt 
mice (Study III). This indicates an increased resistance of DAergic neurons that are under 
influence of permanent Ret activity to neurotoxic insult. Sustained Ret activity probably 
slows down retrograde progression of the damage, leaving cell bodies in the substantia 
nigra mostly unaffected by 6-OHDA, and/or effectively rescues damaged TH-positive 
cells from dying. Our data are in agreement with previous studies showing that 
exogenously provided GDNF per se is neuroprotective against toxins (Tomac et al., 1995; 
Kordower et al., 2000; Schober et al., 2007). On the other hand, loss of physiological Ret 
signaling was shown not to increase the sensitivity against MPTP (Kowsky et al., 2007). 
Taken together, these data suggest that only elevated GDNF/Ret signaling is able to 
protect nigral DA neurons from neurotoxins, whereas physiological GDNF/Ret signaling 
is insufficient to do so.  
While the number of TH-positive nigral cell bodies in the MEN2B mice was 
practically unaffected by 6-OHDA toxicity (showing only a 9% DA cell loss), the toxin 
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profoundly affected the DAergic terminals in the striatum, as revealed by marked DA 
depletion (73%). Also, we found that MPTP similarly reduced striatal DA concentration in 
Wt and MEN2B mice (Study III). Thus, effects of both 6-OHDA and MPTP in the 
striatum of MEN2B mice suggest that the survival-supporting effect of constitutively 
active Ret signaling does not occur at the level of DAergic terminals but most likely in the 
cell body. This view is supported by the findings that application of the GDNF protein 
into the substantia nigra leads to the protection of only the DAergic cell bodies whereas its 
delivery into the striatum leads to preservation of the entire nigrostriatal pathway (Tomac 
et al., 1995; Connor et al., 1999; Kirik et al., 2000a; Kirik et al., 2000b) . In addition, it has 
been proposed that neurotrophic factors may elicit different effects in relation to axonal 
growth and survival when applied locally at the axon or cell body (Kimpinski et al., 1997; 
Watson et al., 2001).  
Previous studies have shown that GDNF does protect axonal terminals against 6-
OHDA and MPTP (Tomac et al., 1995; Kirik et al., 2000a; Kirik et al., 2000b)     
Therefore, the lack of protection of the DA terminals by constitutively active Ret in the 
MEN2B mice suggests that Ret-independent GDNF signaling events might be involved in 
the neuroprotective effects of GDNF against toxin-induced degeneration of striatal DA 
terminals. Also, differences in the signaling properties between MEN2B and wildtype Ret 
could explain lack of protection of striatal DAergic endings in the MEN2B mice.  
It should be noted that we did not examine the DAergic system of toxin-treated 
MEN2B mice at a later time point, and thus did not study the effects of constitutive Ret 
signaling on regeneration of the DAergic system. Therefore, our findings do not rule out a 
possible role for Ret signaling in the regeneration of injured DAergic fibers, as shown by 
Kowsky and co-workers (2007).  
6.8 Increased DAergic transmission and vulnerability of the DA 
system in the MEN2B mice 
There are reports suggesting that dopamine itself is toxic and may cause neuron 
degeneration (Ben-Shachar et al., 1995; Fumagalli et al., 1999; Rabinovic et al., 2000; 
Chen et al., 2008). Also, both MPTP and 6-OHDA enter DA neurons through DAT, which 
is critical for their neurotoxicity (Gainetdinov et al., 1997; Blum et al., 2001). Thus, high 
tissue concentrations of DA and increased DAT activity in the striatum of the MEN2B 
mice (Mijatovic et al., 2007; Mijatovic et al., 2008) could theoretically lead to increased 
vulnerability of DA neurons and even to increased sensitivity to neurotoxins. However, 
our striatal DA-depletion data show that increased tissue DA levels or uptake rate are not 
detrimental in MEN2B mice.It has been shown that VMAT2 plays an important role in 
neurotoxin sequestration into vesicles (Takahashi et al., 1997; Gainetdinov et al., 1998). 
Thus, increased dopamine transporter activity is probably balanced by increased VMAT2 
activity we previously found in the MEN2B mice (Mijatovic et al., 2008). However, we 
cannot completely rule out the possibility that the extent of the striatal lesion may have 
initially been larger in the MEN2B mice, and subsequently counteracted by neurotrophic 
support of increased Ret activity. 
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The lack of a compensatory increase in metabolite/DA ratios that we found in the MEN2B 
mice after administration of neurotoxins could mean that DA terminals in MEN2B mice 
are capable of maintaining DAergic neurotransmission without additionally increasing 
their activity. Alternatively, it might suggest the inability of maximally activated DA 
neurons to further increase their activity.  
Paradoxically, we found an increase in the number of amphetamine-induced rotations 
in the MEN2B mice compared to the Wt mice (Study III). The number of ipsilateral 
rotations after amphetamine challenge is not an accurate indicator of higher degree of the 
lesion. We speculate that amphetamine-induced DA release in the intact side of the 
MEN2B mice probably exceeds that in the Wt mice, thus exaggerating the DAergic 
imbalance between lesioned and intact sides in the MEN2B mice more than in the wild-
type mice and finally resulting in increased rotational behavior in the MEN2B mice. Also, 
lack of a compensatory increase in the DAergic activity in the lesioned striatum of the 
MEN2B mice might contribute to larger imbalance between the sides.  
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7. CONCLUSIONS 
Generally, this study showed that constitutive Ret signaling in mice supports and protects 
brain DA neurons and promotes DAergic phenotype, thus endorsing Ret as an important 
signaling receptor for GDNF in the nigrostriatal DAergic system. 
The more specific conclusions drawn from the results of the present study are: 
 
1. Continuous activity of Ret in the MEN2B mice leads to profound increase in 
brain DA levels and increase in the number of DA neurons in the SNpc. 
Constitutive Ret activity also stimulates synthesis of DA, as revealed by 
increased levels and enhanced activity of TH, the rate-limiting enzyme of DA 
synthesis. The effects of constitutive Ret signaling on the brain DA system start 
during the postnatal life and persist during adulthood.  
 
2. Augmented DA production in the MEN2B mice is accompanied by its 
increased storage in the axonal ending in the striatum. This further leads to 
enhanced DA release, which is compensated for by increased uptake of DA. 
 
3. Constitutive Ret activity in the MEN2B mice provides protection against 
neurotoxins only to the DA cell bodies in the substantia nigra pars compacta 
but not to the axon terminals in the striatum.  
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